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 Myeloid cell leukemia-1 (Mcl-1) is a potent anti-apoptotic protein, member of the anti-
apoptotic Bcl-2 family. Overexpression of Mcl-1 is associated with high tumor grade, resistance 
to chemotherapy, and poor prognosis in many types of cancers. Thus, Mcl-1 is emerging as a 
critical survival factor in a broad range of human cancers and represents an attractive molecular 
target for the development of a new class of cancer therapy.  
 Applying an integrated screening strategy through combining high throughput and virtual 
screenings, multiple hit compounds with structural diversity were validated as Mcl-1 inhibitors 
using biochemical and biophysical methods. Based on the confirmed hit molecule and analyzing 
structure activity relationship (SAR) together with computational docking predicted binding poses 
supported by HSQC NMR studies, we have designed and optimized a novel class of selective 
small-molecule inhibitors of Mcl-1 using a 2,4,5 substituted benzoic acid as a scaffold. Several co-
crystal structures of this class of inhibitors in complex with Mcl-1 have provided a basis for their 
further optimization, which ultimately led to the discovery of nanomolar potent and selective 
ligands that bind to the BH3 hydrophobic groove of the Mcl-1 protein. Mechanistic studies 
performed in genetically engineered cell lines revealed that our inhibitors have on-target activity 
and induce Bax/Bak dependent apoptosis; selectively antagonizing Mcl-1 function leading to the 
induction of the hallmarks of apoptosis. Using functional BH3 profiling assay, we identified 
heterogeneous dependency on Bcl-2 family members for survival in hematologic malignancies, as 
well as in solid human cancers. The mitochondrial response to selective Mcl-1 BH3 peptides (Noxa 
and MS1) predicted the in vitro sensitivity to Mcl-1 inhibitors of several cell lines found to be Mcl-
1 dependent, including multiple myeloma cell line H929. 483LM, one of the most potent 
developed Mcl-1 inhibitors, inhibited the cell growth and induced mechanism-based apoptotic cell 
death in the H929 cells. Intraperitoneal treatment of the H929 cancer xenograft model with 483LM 
led to significant dose-dependent tumor regression. Collectively, our data demonstrates that the 
xiii 
 
new class of Mcl-1 inhibitors has promising in vitro and in vivo efficacy, warranting further 
development toward clinical use in the treatment of human cancers. 
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CHAPTER 1  
Introduction 
 
1.1 Hallmarks of cancer 
 
 Cancer is major worldwide disease that is considered the second most common cause of 
death after cardiovascular diseases.[1] Globally, there are tens of millions of people who are 
diagnosed with cancer.  More than half of the diagnosed cancer patients die eventually from the 
disease. The increased aging population is of high risk of developing cancer, causing the disease 
to be a worldwide health issue. 
The debilitating health problems of cancer led to extensive researches to be conducted in 
order to understand the disease, its risk factors, and the means of treatment. There is now a 
fundamental change in the way cancer research is conducted. Cancer research is becoming a 
logical science with a tendency to break down disease complexity into simple underlying 
principles.  
 It is evident that the transformation of normal cells to tumors is a process that includes 
several steps of genetic changes.  Based on the suggestions of Hanahan and Weinberg, 
tumorigenesis is a result of six alterations or traits in cell physiology which are collectively named 
“Hallmarks of Cancer” (Figure 1.1).[2] The six hallmarks are 1) Sustained growth signals, 2) 
Evading anti-growth signals, 3) Activated invasiveness and metastasis, 4) Evading apoptosis, 5) 
Limitless replication potential, and 6) Angiogenesis. These six core hallmarks are acquired during 
tumorigenesis through various mechanisms which are enabled through two major characteristics. 
The first is genetic instability and mutations which lead to changes in the genetic makeup of cells 
driving tumorigenesis, and the second is the inflammatory state of the tumor where inflammation 
provides the tumor with sustaining bioactive molecules to promote its proliferation, limitless 
growth, and cell death resistance.[3, 4] 
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  In the recent decade, some other characteristics in tumors are suggested to be important in 
tumorigenesis. There are two emerging hallmarks that could be added to the six hallmarks 
mentioned above. The first one is the alteration of the cellular energy metabolism of cancers 
compared to normal tissues, and the second is ability of tumor to evade immune cells and avoid 
detection by the immune system and consequent eradication. Further studies are required to 
understand those two emerging hallmarks in order to confirm their generality in all types of cancer 
and subsequently considering them part of the core hallmarks of cancer.  
 The great progress in understanding cancer resulted in the emergence of mechanism-based 
cancer therapeutics. These types of therapeutics possess the advantage of having, in principle, less 
side effects compared to chemotherapy. However, there are still challenges in mechanism-based 
therapeutics since tumors can still survive and adapt to the selective pressure imposed by the 
therapy. As a result, targeting several cancer hallmarks and drug combinations might be the best 
approach to overcome tumor resistance. In this thesis study, we are interested in the ability of 
cancer to evade cell death; particularly apoptosis, and the development and characterization of 
novel small molecules that block this cancer hallmark.  
 
 
Figure 1.1.Hallmarks of cancer and the potential therapeutic targeting mechanisms. The 




1.2 Apoptosis and regulation of cell death 
 
 Apoptosis (programmed cell death) is a controlled cell death mechanism that provides a 
way to degrade damaged cells via a non-inflammatory process. It is a normal process that occur 
during development and aging and as a homeostatic mechanism in order to maintain cell 
populations in tissues. The term “apoptosis” was first introduced and described in a paper by Kerr 
et al 1972.[5] Apoptosis is characterized by nuclear condensation, shrinking of cells, blebbing of 
cell membrane, and DNA fragmentation. Consequently, the cells break down their components to 
be eventually engulfed by white blood cells. This process is different from necrosis where the cells 
release cellular contents to the surrounding tissues and cause damage. [6] Any dysregulation in the 
process of apoptosis can lead to development of diseases. Excessive apoptosis can cause 
degenerative disorders while  increased cell survival can lead to cancer, which is the focus of my 
thesis study.[7] Apoptosis is activated in response to intracellular signals such as DNA lesions, 
defects in mitosis, oxidative stress, or other stresses e.g. certain drugs or UV light (intrinsic 
apoptotic pathway). Activation can also be due to extracellular signals emitted by other cells 
(extrinsic apoptotic pathway) (Figure 1.2).[8, 9]  
 The activation of the intrinsic apoptotic pathway leads to the activation of B-cell 
lymphoma-2 (BCL-2) family proteins. Consequently, the mitochondria undergo mitochondrial 
outer membrane permeabilization (MOMP), causing the efflux of cytochrome c as well as the 
second mitochondrial activator of caspases (Smac).  Cytochrome c binds to the apoptotic protease 
activating factor 1 (APAF1), and recruits procaspase 9 for the apoptosome. Apoptosomes cleave 
procaspase 9 to caspase 9 which in turn activates caspases 3 and 7, inducing the cleavage of poly 
ADP ribose polymerase (PARP) and ultimately apoptosis. Several ubiquitin ligases are involved 
in the inhibition of cell death, e.g. X-linked Inhibitor of Apoptosis Proteins; (XIAP). Smac 
indirectly promotes apoptosis by blocking the effects of XIAP. 
 The extrinsic apoptotic pathway is activated when the death ligands, such as FASL, TNF-
related apoptosis-inducing ligand (TRAIL), or tumor necrosis factor-α (TNFα) bind to their 
corresponding death receptors FASR, TNFR and DR4/5 respectively. The binding forms the death-
inducing signaling complex (DISC) which activates caspase 8 and 10, leading to the subsequent 
activation of caspases 3 and 7. The extrinsic apoptotic pathway activation mediates the truncation 
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of the pro-apoptotic protein Bid to the truncated form (tBid) by caspase 8, which in turn translocate 
to mitochondria and activates MOMP through the intrinsic apoptotic pathway.[10]  
 
Figure 1.2.Simplified illustration of the intrinsic and extrinsic pathways of apoptosis. 
 
1.3 Bcl-2 family proteins 
 
 Bcl-2 (B-cell lymphoma-2) proto-oncogene was discovered at the chromosomal breakpoint 
of t(14;18) bearing human B-cell follicular lymphomas.[11] The number of Bcl-2 family members 
has expanded significantly and included both pro-apoptotic (promoting apoptosis) and anti-
apoptotic (inhibiting apoptosis) proteins. The ratio between the two groups of proteins regulates 
the ability of cells to respond to the death signal.[12] The members of have the ability to form 
homodimers as well as heterodimers, suggesting neutralizing competition between these proteins. 
Proteins of the Bcl-2 family possess blocks of sequence homology known as Bcl-2 homology (BH) 
domains. There are six anti-apoptotic proteins Bcl-2, Bcl-xL, Bcl-w, Bcl-b, A1, and myeloid cell 
leukemia sequence 1 (Mcl-1), and three pro-apoptotic effector proteins Bax, Bak, and Bok and 
they all share four BH domains (BH1-4).[13] They have similar globular structures; several α-
helices where a hydrophobic pocket is formed by α-helices 2,3,4 and 5.[14] This pocket interacts 
with the BH3 domain of pro-apoptotic BH3-only proteins (Bim, tBid, Puma, Bad, Noxa, Bik, Hrk 
and Bmf) (Figure 1.3a). 
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 BH3-only proteins contain only the BH3 amphipathic α-helix, which mediate their 
interaction with the groove of multi-domain Bcl-2 family members. The BH3-only proteins bind 
to the BH3 binding hydrophobic groove of anti-apoptotic proteins through interactions between 
four conserved hydrophobic residues (h1-4) and four hydrophobic pockets (P1-4) of anti-apoptotic 
proteins, and the conserved hydrogen bond between Asp residue of BH3-only protein and Arg 
residue in anti-apoptotic proteins BH1 domain (Figure 1.3b). [15, 16] 
 
Figure 1.3.Structure of Bcl-2 family proteins and conserved interactions between BH3-only 
and anti-apoptotic proteins. 
 
 BH3-only proteins have different binding profiles to the anti-apoptotic proteins. Some 
show selective binding, for example, Noxa interacts only with Mcl-1 and A1, while Bad interacts 
with Bcl-2, Bcl-xL and Bcl-w (Figure 1.4). However, some BH3-only proteins show promiscuity 
and bind to all anti-apoptotic proteins including tBid, Bim, and Puma. The flexibility of the BH3 
binding pocket contributes to the ability of anti-apoptotic proteins to bind to several pro-apoptotic 
partners.[17] In addition to BH domains, most family members have a transmembrane (TM) 




Figure 1.4.Selectivity of interactions among the Bcl-2 family of proteins. 
 When the intrinsic apoptotic pathway is activated, pro-apoptotic BH3-only proteins are 
induced transcriptionally or post-translationally.[19] There are two proposed mechanisms by 
which the BH3-only proteins carry out their pro-apoptotic function. [20, 21] The first is 
neutralization of the anti-apoptotic proteins and indirect activation of effectors Bax and Bak 
(Figure 1.5a). This mechanism has been well studied on structural and functional levels, 
encouraging the development of novel therapeutics that target the anti-apoptotic proteins. When 
the intrinsic pathway is activated, the BH3-only proteins bind to anti-apoptotic proteins and cause 
the release of activated Bax and Bak, triggering the apoptosis cascade. 
 The second proposed mechanism suggests the direct activation of Bax and Bak. In this 
mechanism the BH3-only proteins are subdivided into activators which directly activate Bax and 
Bak (tBid, Bim, or Puma), and sensitizers which are not able to directly activate Bak or Bak (Noxa, 
Bad, etc.). On activation of the intrinsic pathway, sensitizers bind to anti-apoptotic proteins and 
release the activators which in turn activate Bax and Bak (Figure 1.5b). The current consensus is 
that both models play a role in the pathway. In the unified model, sensitizers bind to anti-apoptotic 




Figure 1.5.Proposed models of interactions of Bcl-2 family proteins. (A) Indirect activation 
model, (B) Direct activation model, and (C) Unified model. 
 It seems that some cells display predominantly a certain model over the other and that could 
be attributed to the types of cells under investigation or the types of stimuli that triggers activation 
of the intrinsic apoptotic pathway (Figure 1.5c). When the intrinsic apoptotic pathway is triggered, 
Bak is activated and homo-oligomerizes to induce MOMP. Although Bak resides on the 
mitochondria, Bax is a cytosolic protein which accumulates on the mitochondria and homo-
oligomerize when apoptosis is triggered (Figure 1.2).[23, 24] 
1.4 Bcl-2 family proteins as therapeutic targets for cancer 
 Understanding the apoptosis mechanisms and the immense structural knowledge of the 
Bcl-2 family of proteins introduces the idea of developing inhibitors that can inhibit the function 
of anti-apoptotic proteins. These inhibitors could be crucial in the fight against cancer. Many 
studies have shown that elevated levels of anti-apoptotic proteins are frequently observed in 
cancer.[25] This usually leads to resistance to various chemotherapeutics. In the past years, the 
anti-apoptotic protein families have been targeted in cancer treatment strategies. Several types of 
inhibitors of anti-apoptotic proteins have been developed, including peptidomimetics [26, 27] and 
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antisense oligonucleotides.[28] Consequently, the development of small-molecule BH3 mimetics 
that block anti-apoptotic proteins became a promising approach to disrupt the interaction with the 
bound pro-apoptotic proteins and force cancer cells to undergo apoptosis. Developing small 
molecules targeting these protein-protein interactions is a challenging process. However, there are 
number of BH3 mimetics reported to trigger apoptosis undergoing extensive clinical and 
preclinical studies. Obatoclax (GX015-070), which is derived from prodiginines, is a pan-inhibitor 
of Bcl-2 family proteins.[29, 30] Several studies on Obatoclax suggest that it is effective as a single 
agent or in combination therapy (Figure 1.6). It is under phase III clinical trials, but the 
development of neurotoxicity as a side effect might hinder its progress as a drug.[31] Gossypol 
(AT-101) is another anticancer agent that has shown inhibition of Bcl-2, Bcl-xL and Mcl-1.[32] 
Gossypol is currently in clinical trials.[33] A derivative of Gossypol, TW-37, is another pan-
inhibitor that shows promising results as a single agent and in combination with other agents. [34-
36] Abbvie team spearheaded the drug discovery efforts to develop BH3 mimetics that target anti-
apoptotic proteins. The team developed ABT-737 as a potent inhibitor of Bcl-2, Bcl-xL and Bcl-
w. [37] This compound and its orally available analog ABT-263 (Navitoclax) have been 
extensively studied to confirm their modes of action.[38, 39] Clinical trials of ABT-263 were 
carried out for treatment of lymphoid malignancies and chronic lymphocytic leukemia.[40, 41] 
Significant thrombocytopenia was reported in clinical trials which was attributed to inhibiting Bcl-
xL protein from circulating platelets. This led to the development of ABT-199 (Venetoclax) which 
shows selective binding to Bcl-2.[42] ABT-199 progressed to clinical trials.[43] The U.S. Food 
and Drug Administration (FDA) approved Venetoclax for the treatment of patients who have 
chronic lymphocytic leukemia (CLL) with a chromosomal abnormality called 17p. Venetoclax is 
the first FDA-approved treatment that targets Bcl-2 family proteins. However, Mcl-1 mediates 
resistance to Bcl-2 and Bcl-xL inhibitors, including ABT-199, because they fail to inhibit Mcl-




Figure 1.6.Structure of small-molecule inhibitors of Bcl-2 family proteins. 
 
1.5 Efforts to develop small-molecule Mcl-1 inhibitors 
 Mcl-1 has been observed to be highly expressed in various of human cancers including 
melanoma, multiple myeloma, pancreatic, colon, and hematological malignancies.[45] The 
overexpression of Mcl-1 contributes to the ability of cancer cells to evade cell death. Mcl-1 
overexpression is considered a resistance mechanism deployed by cancer against 
chemotherapeutic agents. Downregulation of Mcl-1 in resistant types of cancer increases their 
sensitivity to chemotherapeutics.[46-48] Thus, developing Mcl-1 inhibitors has been a hot topic of 
research in the past few years. There are several approaches designed to target Mcl-1, either 
directly through blocking its BH3 binding site, or targeting upstream pathways that upregulate its 
degradation [49], or downregulating its protein level through inhibition of expression [50], or 
translation. [51] 
 Developing selective small-molecule BH3 mimetics to inhibit Mcl-1 has been far from 
trivial. Despite the extensive efforts to develop potent and selective small molecules, to date there 
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are no Mcl-1 inhibitors that reached clinical trials. Several small-molecule potent and selective 
inhibitors of Mcl-1 have been developed and well characterized. Using high throughput screening 
(HTS) of 53,000 compounds and optimization of hit compound UMI-59, the selective Mcl-1 
inhibitor UMI-77 (Ki = 490 nM) was developed and exhibited Bax/Bak dependent induction of 
apoptosis and caspase-3 activation in pancreatic cancer cell lines (Figure 1.7). In vivo studies using 
the pancreatic xenograft model showed effective inhibition of tumor growth by UMI-77.[52] The 
more potent analog 21 (Ki = 180 nM) showed similar selectivity profile as UMI-77. 21 inhibited 
leukemia cell growth, and showed dose-dependent induction of apoptosis and activation of 
caspase-3 in the HL60 cell line. Further, similar to UMI-77, compound 21 showed Bak/Bax-
dependent induction of cell death. [53] Walensky’s lab successfully identified a selective Mcl-1 
inhibitor MIM1 (IC50 = 4.78 µM) using HTS of 70,000 compounds.[54]  
 
Figure 1.7.Structure of small-molecules selective Mcl-1 inhibitors. 
 MIM1 was able to show Bax/Bak dependent induction of apoptosis in leukemia. Using 
fragment based screening, Fesik’s lab developed compound 53 (Ki = 55 nM) as a selective Mcl-1 
inhibitor. 53 was the first small molecule to be co-crystallized with Mcl-1, which was a 
breakthrough in aiding the structure-based drug design efforts.[55] This compound led to further 
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development of the more potent analog 60 (Ki = 0.36 nM).[56] Despite the high potency of this 
compound, it did not show permeability in PAMPA assay, which hindered its biological 
characterization. Abbvie team developed a potent and selective Mcl-1 inhibitor, A-1210477 (Ki = 
0.43 nM). This compound exhibited promising results in several cell lines, including multiple 
myeloma, breast cancer, and pancreatic cancer, either as a single agent or in combination with 
Navitoclax.[57, 58] However, no in vivo studies have been conducted using this inhibitor. Thus 
there is still a need for Mcl-1 inhibitors that can exhibit solid biological characterization and in 
vivo efficacy which can be taken further to clinical studies.  
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CHAPTER 2  
Utilization of PubChem’s BioAssay Database for drug discovery: Integrated HTS and 




Protein-protein interactions (PPIs) play a crucial role in regulating many biological 
functions. Advances in genomics and proteomics have shaped our understanding of PPIs. 
Dysregulation of PPIs is the basis of many diseases, including cancer. Our growing understanding 
of cancer biology raised interest in targeting PPIs for the treatment of cancer.[1] A major challenge 
in PPIs is developing small molecules that target these relatively flat and large interfaces.[2] Many 
of these protein interfaces are hydrophobic in nature so the developed drug leads are often 
hydrophobic with high molecular weight. These physicochemical properties are usually 
unfavorable for drug candidates due to low solubility, cell permeability, or oral bioavailability.[3] 
Although developing small molecules that target PPIs is challenging, there are successful examples 
of compounds that exhibit highly potent and selective inhibition to their designated targets and 
some have been FDA approved in the last few years.  
 There are numerous PPIs that have a pivotal role in the development of the hallmarks of 
cancer and maintaining its uncontrolled proliferation.[4] For example, the activation of Ras via 
mutated epidermal growth factor receptor (EGFR), or Neurofibromin 1 (NF1) mutation or deletion 
resulted in continuous proliferation of cancer cells and resistance to cell death.[5, 6] The same 
hallmark occurs with the XIAP/Caspase 9 interaction and Bcl-2 family pro- and anti-apoptotic 
proteins.[7, 8] Some PPIs such as Mouse Double Minute 2 homolog (MDM2)/p53 and Cyclin-
dependent kinase 4 (CDK4)/retinoblastoma protein (pRB) lack tumor suppressive functions[9, 10] 
Epigenetic aberrations in PPIs also play a role in cancer development.[11] Since several PPIs are 
involved in tumorigenesis, inhibiting them can block several pathways that the cancer 
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depends on for survival and proliferation. Thus, targeting PPIs can be of great importance in the 
field of anticancer drug discovery.[12] 
 
2.2 Approaches and strategies to identify inhibitors of PPIs 
 
 The rational design of PPI inhibitors (PPII) has improved dramatically thanks to the 
increasing structural and functional knowledge of PPIs. There are numerous approaches that are 
employed in order to identify and optimize inhibitors of PPIs. 
 
2.2.1   High-throughput screening (HTS)  
 
 HTS has been used to identify small molecules that can bind to the PPI interface’s hot 
spots. HTS is usually coupled with structure-based design in order to develop inhibitors with better 
activity and physicochemical properties.[1] Fluorescent polarization (FP) and time-resolved 
fluorescence resonance energy transfer (TR-FRET) are the most frequently used techniques in 
HTS campaigns. [13] Some other techniques are surface plasmon resonance (SPR), flow 
cytometry, and enzyme-linked immunosorbent assay (ELISA).[14]  HTS has also been performed 
to identify fragments that target the PPI (fragment based screening). Since these fragments usually 
have a low affinity to the target, highly sensitive biophysical techniques for screening are used, 
such as X-ray crystallography, nuclear magnetic resonance (NMR), and surface plasmon 
resonance (SPR) to identify hits.[15-17] Following optimization of initial fragment hits, small 
molecules can be designed to take advantage of the fragments’ scaffolds and identify interactions 
with the target protein.[18, 19] Some examples of successful fragment based screening campaigns 
were used to identify inhibitors for Mcl-1, Bcl-2, XIAP and HSP90.[20-23] 
 
2.2.2  Virtual screening 
 
 There are two methods of virtual screening. The first one is pharmacophore-based virtual 
screening where a model is designed to take advantage of key chemical features of a group of 
compounds that are known to bind to the target proteins. These features aid in identifying 
compounds that align with the requirements of the model. Some successful examples are the 
development of MDM2 and Bcl-xL inhibitors.[24, 25] The second method is structure-based 
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screening where the approach depends on identifying key hot spots in the binding site of the 
targeted protein. In this method the screened compounds are docked into the binding site and the 
binding affinity is predicted. Using this approach, several inhibitors has been successfully 
identified against MDM2 and β-catenin.[26, 27] 
 
2.3 Reported Mcl-1 inhibitors 
 
 Myeloid cell leukemia-1 (Mcl-1) is a member of the anti-apoptotic Bcl-2 family proteins. 
[28] Increased levels of anti-apoptotic Bcl-2 proteins are connected with the maintenance of 
malignant diseases, resistance to chemotherapy, and poor clinical outcomes. [29] Strategies 
seeking to inhibit the function of anti-apoptotic Bcl-2 proteins have been extensively studied for 
developing novel cancer therapies. [30] Previous studies employing different approaches 
identified a number of promising Mcl-1 inhibitors with unique scaffolds. As discussed in chapter 
1, Obatoclax is a pan-inhibitor of Bcl-2 family of anti-apoptotic proteins (Figure 2.1). [31] Several 
analogs were developed based on Obatoclax scaffold such as pyrrolyl-methylene-pyrrolyl-indole 
(SC-2001) [32], which shows more potent cellular activity compared to Obatoclax.[33] Another 
pan-inhibitor is Gossypol with a binaphthalene scaffold.[34] Apogossypol (Sabutoclax), a more 
potent derivative of Gossypol, is developed based on the same scaffold. Other derivatives of 
Gossypol, such as BI97C10 and BI112D1, were also developed. [35-37] TW-37 is a second 
generation benzenesulphonyl derivative of Gossypol which exhibits pan inhibition to anti-
apoptotic proteins. [38] Several unique scaffolds were reported as selective Mcl-1 inhibitors. For 
example, MIM1 with a methylthaizol scaffold exhibits low micromolar inhibition of Mcl-1 [39]. 
As mentioned in Chapter 1, we described small-molecule selective Mcl-1 inhibitors (UMI-77 and 
compound 21) with hydroxynaphthalen-arylsulfonamide core scaffolds, and demonstrated their 





Figure 2.1.Reported scaffolds of small-molecule Mcl-1 inhibitors. 
 
 Recently, two groups described the synthesis of Mcl-1 inhibitors containing indole-2-
carboxylic acid cores. Fesik’s group described the synthesis of Mcl-1 inhibitors (53 and 60) with 
low nanomolar and subnanomolar binding affinities respectively, but the compounds lack 
sufficient permeability and failed to show cellular activity.[22, 44] Abbvie group developed an 
Mcl-1 inhibitor (A-1210477) with subnanomolar affinity and on-target cellular activity in cell lines 
that rely on Mcl-1 for survival, but no in vivo efficacy studies were conducted with this 
compound.[45, 46] 
 All of the above reported inhibitors with their unique scaffolds are targeting the BH3-
binding groove to inhibit the function of anti-apoptotic Bcl-2 family proteins. [29, 30] Each of the 
six members of the anti-apoptotic Bcl-2 family proteins, Bcl-2, Bcl-xL, Mcl-1, Bcl-2, Bcl-w and 
A1, has 8 – 9 α-helices and a ~20 Å hydrophobic cleft, the “BH3-binding groove”. As described 
in Chapter 1, the BH3 domain of the pro-apoptotic Bcl-2 family proteins possesses four conserved 
hydrophobic residues with three to four residues apart (Figure 1.3b), which insert into the four 
hydrophobic pockets (P1-4 pockets) within the BH3-binding groove of the anti-apoptotic Bcl-2 
family proteins (Figure 2.2). Additionally, a conserved aspartic acid forms a salt bridge with a 
conserved arginine on the anti-apoptotic Bcl-2 family proteins. [30] These Mcl-1 inhibitors, as 
demonstrated by the X-ray crystallography and Heteronuclear Single Quantum Coherence NMR 
spectroscopy (1H, 15N HSQC NMR) studies coupled with docking studies, can mimic at least two 
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conserved interactions of the four interactions observed for the BH3-only peptides (hydrophobic 
interactions in the P2, P3 and P4 pockets and hydrogen bonds with the conserved Arg 263).  
 In order to identify and enrich the diversity of the chemical scaffolds as Mcl-1 inhibitors, 
and at the same time to take advantage of the structural information and interactions between pro- 
and anti-apoptotic proteins, we applied an integrated screening approach by combining HTS and 
structure-based virtual screening approaches.  
 
Figure 2.2.Interaction of conserved residues of pro-apoptotic proteins with anti-apoptotic 
proteins. Mcl-1 and Bim complex structure (PDB ID: 2PQK) 
 
2.4 Results 
2.4.1 Integrated screening for identification of novel small-molecule Mcl-1 inhibitors 
   
PubChem, hosted by the NIH, is a free public repository for the chemical structures and 
their biological results, contributed by more than a hundred organizations. [47, 48] Three 
interconnected databases comprise PubChem: Substance, BioAssay, and Compound. Bioactivity 
information generated by high-throughput screenings (HTS) and medicinal chemistry studies is 
deposited in the BioAssay database. [49, 50] It holds bioactivity results from more than 1600 HTS 
programs and covers around 10000 unique protein targets and 30,000 gene targets with over 130 
million bioactivity outcomes and thus makes it an excellent resource for the chemical biology and 
the drug discovery community. [49, 50] This is reflected by the fact that the number of research 
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publications using the PubChem chemical library and bioassay data has increased rapidly since the 
launch of PubChem. [51]  
We have previously reported two optimized ultra-HTS time-resolved fluorescence 
resonance energy transfer (TR-FRET) based assays to screen 102,255 compounds. The results 
from this screen were deposited into the PubChem’s BioAssay Database as: AID 1417 reporting 
the dose response confirmation of Mcl-1/Noxa interaction inhibitors[52], and AID 1418 dose 
response confirmation for Mcl-1/Bid interaction inhibitors[53]. 875 compounds, identified with 
AID 1417 assay and 509 compounds from AID 1418 assay with 170 common compounds, were 
confirmed after secondary dose dependent screening.  
 In order to incorporate the known structural information between pro- and anti-apoptotic 
proteins, a computational structure-based screening strategy was integrated in the next step. This 
was followed by biochemical and biophysical binding methods to validate and confirm the 
identified inhibitors to the Mcl-1 protein (Figure 2.3)  
 





 The 1214 identified hits from the two performed HTS assays were docked into the active 
site of the Mcl-1 protein using the X-ray co-crystal structure between Noxa BH3 peptide and Mcl-
1 (PDB ID: 2NLA). The goal of integrating structure-based screening was to determine whether 
or not these compounds could dock into the BH3 binding groove of the Mcl-1 protein and mimic 
the conserved interactions of the BH3-only peptides with Mcl-1. [54] Considering the high 
flexibility and adaptability of the anti-apoptotic Bcl-2 family proteins, the Schrödinger’s Induced 
Fit Docking (IFD) protocol was employed for the docking studies. [55],[56] The center of the grid 
box of the Mcl-1 that was used in the virtual screening was defined by the Phe 270 (in the p2 
pocket), Val 220 (in the p3/p4 pocket), Val 216 (in the p4 pocket), as well as charged Arg 263.
 Generated docking poses were visually examined for predicted binding geometries and 
analyzed the interactions between the compounds and the Mcl-1 protein. 67 compounds with 
reasonably predicted poses that mimicked at least two conserved interactions of BH3 peptides with 
the Mcl-1 protein (hydrophobic interactions with p1, p2, p3, or p4, and hydrogen bond interaction 
with the Arg 263 residue) were selected for further studies. 37 compounds were purchased to be 
carefully validated as potential Mcl-1 inhibitors. The chemical structures of these compounds 
cover a diverse chemical space (Table 2.1). 
 
2.4.2 Biochemical assays and 1H,15N HSQC NMR validation experiments 
 
 To validate the most promising from the list of 37 potential Mcl-1 inhibitors obtained after 
integrated screening, we applied biochemical and biophysical methods. Using established and 
optimized FP-based competitive assay, with Flu-BID-BH3 peptide as the fluorophore probe and 
the SPR-based competitive binding assays using biotin (BL) labeled Bim BH3 peptide, would 
allow us to demonstrate that these inhibitors can competitively displace different BH3 pro-
apoptotic proteins. The biophysical method, 1H,15N HSQC NMR spectroscopy was conducted to 
conclusively confirm that identified compounds directly bind to Mcl-1 protein. Assigning residues 
of 15N labeled Mcl-1 protein allowed us to identify the residues which show chemical shift, map 
the binding site, support the predicted docking pose, and confirm that the compounds bind to the 
BH3-binding groove. Twenty compounds (labeled from 1 to 20) were confirmed with these three 
binding assays. Their chemical structures and binding results are presented in Table 2.1. Fourteen 
compounds showed similar binding affinities to the HTS results in one or both SPR and FP assays. 
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Two compounds, 13 and 29, showed auto fluorescence, and thus were tested only with SPR 
competitive binding assay and HSQC NMR.  Compound 13 was confirmed in both of these assays. 
Compound 29 showed significant lower IC50 value in the SPR competitive binding assay, 25 to 50 
fold, in comparison with the HTS dose response data, so we did not proceed to test this compound 
with HSQC NMR assay.  
  





































































1.87±0.17 4.14±0.36 1.90 1.67 + 
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9.43±3.81 2.79±0.86 3.74 N.D. + 
13 
 
N.D. 10.70±4.20 1.71 N.D. + 
14 
 
17.87±2.10 66.08±7.98 9.55 N.D. + 
15 
 




















23.66±1.64 14.91±0.69 N.D. 0.54 + 
19 
 
11.14±1.76 50.02±9.27 7.19 N.D. + 
20 
 
13.77±1.39 13.44±0.20 3.11 N.D. + 
21 
 
17.00±3.06 33.80±5.80 3.91 0.53 - 
22 
 
N.C. N.C. 7.21 16.95 N.D.d 
23 
 
N.C N.C 1.7 N.D. N.D. 
24 
 
N.C. N.C. 3.44 9.94 N.D. 
25 
 
N.C. N.C. 3.14 N.D. N.D. 
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N.C. N.C. N.D. 1.76 N.D. 
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140.70±18.82 >100 N.D. 0.57 N.D. 
31 
 
N.C. N.C. 2.91 0.46 N.D. 
32 
 
N.C. N.C. 2.91 0.58 N.D. 
33 
 
N.C. N.C. 4.90 N.D. N.D. 
34 
 
N.C. N.C. 1.15 N.D. N.D. 
35 
 
N.C. N.C. 2.31 9.29 N.D. 
36 
 
N.C. N.C. 5.07 N.D. N.D. 
37 
 
N.C. N.C. N.D. 0.84 N.D. 
a This is the IC50 value deposited into PubChem’s BioAssay (AID 1417: Dose Response Confirmation for Mcl-
1/Noxa Interaction Inhibitors). 
b This is the IC50 value deposited into PubChem’s BioAssay (AID 1418: Dose Response Confirmation for Mcl-
1/Bid Interaction Inhibitors). 
C N.C. Not confirmed. d N.D. Not determined. 
 
 Compound 21 was confirmed in both biochemical assays, but we were not able to confirm 
the direct binding to Mcl-1 using HSQC NMR because of low solubility and precipitation in the 
sample. The remaining compounds (22 to 37) were considered as non-confirmed due to their 
unfavorable binding behavior either in the FP or SPR assays or both assays. The non-confirmed 
compounds were not tested further in the 1H,15N HSQC NMR experiments. In Figure 2.3 the 
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binding modes of selected validated hit compounds 9, 14, 15, 16 and 20 along with the 
corresponding obtained 1H,15N HSQC NMR data are presented. Data for the remaining confirmed 
compounds can be accessed in the Chapter Appendix.   
 It was confirmed that all compounds bind to the BH3 binding groove. Compound 9 
occupies the p2 and p3 hydrophobic pockets in Mcl-1, thus mimicking the two conserved 
interactions between p2 and p3, conserved hydrophobic residues from the BH-3 mNoxaB, Leu78 
and Ile81 present in 2NLA, respectively (Figure 2.3a). The trimethylphenyl group occupied the p2 
pocket and Val243, Met250, Val253, Leu267 and Phe270 residues are highly perturbed in the 
obtained NMR. The naphthalenyl ring of 9 resides in the p3 pocket where Val220 showed 
significant chemical shift. The carboxylic group of 9 forms hydrogen bond interactions with 
Arg263 similar to the conserved aspartate in pro-apoptotic BH-3 proteins. This is confirmed by 
the significant perturbation of this residue. As a result, the binding model derived from the docking 
model aligns well with the chemical shift perturbations generated from the HSQC NMR 
experiments. It should be noted that the scaffold of 9 closely resembles the class of selective Mcl-
1 inhibitors that was developed by our group based on another HTS performed at the University 
of Michigan, providing further validation of the integrated screening strategy. [41, 43]   
Based on the predicted binding model generated from molecular docking (Figure 2.3b) hit 
compound 14 interacted with the p2 and p3 pockets. The proposed model is in accordance with 
the obtained 1H,15N HSQC NMR data where the 3-chlorophenyl moiety’s occupation of the p2 
pocket was proven by chemical shift perturbations of Val243, Val249, Met250, and Val253 
residues. In the docking model, the 6-furyl occupied the interface of P2 and P3 pockets, and 
Phe270 and Met231 were observed as highly perturbed in the NMR. In addition, Arg263 residue 
was also showing perturbations, confirming the proposed interaction with the 4-carboxylic acid of 
14. 
 In the docking studies, confirmed hit compound 15 was predicted to occupy the Mcl-1 p2 
pocket while its benzoic acid part interacted with the Arg263 residue (Figure 2.3c). Using HSQC 
NMR, we observed significant perturbations in the Met231, Val243, Met250, Val253, and Phe270, 
all pointing to the potential interaction of the ligand with the Mcl-1 p2 pocket. Arg263 was also 
significantly perturbed, which was in accordance with the proposed docking interaction of the 
carboxylic group present in 15. Our group developed a series of Mcl-1 inhibitors based on this 
validated hit, and recently published the patent describing this class of compounds.[57]   
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 Compound 41 binding mode suggested interactions with the p2 and p3 Mcl-1 hydrophobic 
pockets (Figure 2.3d). Significant NMR shifts were observed for Val243, Val253 and Phe270 
residues being in line with the predicted interaction exhibited by the thiophene moiety of 16 with 
the Mcl-1 p2 pocket. Arg263 residue also showed perturbation in the HSQC NMR experiment 
which provided more confidence in the predicted interaction of the 2-hydroxy phenyl moiety of 
16 with this residue. Interestingly, compound 16 possesses a similar scaffold to a reported Mcl-1 
inhibitor, MIM1, by the Walensky group, outlining another compound to validate the applied 
screening procedure with literature data.[39]  
 The binding of the hit compound 20 (E238) to the Mcl-1 protein was also analyzed based 
on the determined HSQC NMR (Figure 2.3e). As previously confirmed compounds, the analysis 
of the obtained HSQC chemical shift changes displayed that compound 20 affected several amino 
acid residues forming the Mcl-1 BH3-binding groove. The significant NMR shifts of several p2 
residues Lys234 and Leu235 confirmed the generated docking model of 20, where the terminal 
phenyl ring occupies the pocket. Arg263 was also significantly perturbed in the NMR studies, 
which aligned with the predicted interaction with oxygen of the furan ring.  
 More precisely, in the produced IFD binding model, hydrogen bonds formed by the oxygen 
atom of one furan ring, one nitrogen atom of the triazine ring of compound 20, and two residues 
(Asp 263 and Asn 260 of the protein of Mcl-1), can be observed mimicking the conserved aspartate 
in pro-apoptotic BH3 proteins. The phenyl ring of 20 projects into the conserved hydrophobic 
pocket 2 (p2), mimicking one conserved hydrophobic residue of many different BH3 peptides. 
Additionally, another furan ring has weak hydrophobic interaction with residues of Phe318 and 
Phe319, which are proximal to the p4 pocket. These two residues contribute to the additional 
hydrophobic contacts with a hydrocarbon staple of a reported stabilized α-helix of the Bcl-2 
domain.[39, 58] The sulfur-acetamide chain did not have direct interactions with the protein of 
Mcl-1, playing the role as a linker. With the confirmed binding of 20 (E238) and the relatively 
facile synthetic modification that could be applied on that compound, we decided to proceed by 
synthesizing several analogs based on the 1,2,4-triazine scaffold, outlining the exemplary next step 





Figure 2.3. Predicted binding poses and the HSQC NMR analysis of the selected hit 
compounds 9 (A), 14 (B), 15 (C), 16 (D) and 20 (e). Left: Computational predicted binding poses 
of the hit compounds in Mcl-1 binding site using the mNoxa BH3 peptide-bound Mcl-1 crystal 
structure (PDB ID: 2NLA). Orange: hydrophobic surface of the protein; blue: hydrophilic surface 
of the protein. The hydrogen bonds are indicated by magenta lines. Right: Chemical shift 
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differences for Mcl-1 in the presence of these corresponding compounds (2 equivalents) against 
residue number. 
 
2.4.3 SAR investigation of the validated hit compound 20 
 
 We wanted to gain further insight into the structure-activity relationship (SAR) of the 
validated hit compound E238 (20), 2-[(5,6-di-2-furanyl-1,2,4-triazin-3-yl)thio]-N-phenyl-
acetamide, with the determined IC50 value of 13.77±1.39 µM in the FP assay of Mcl-1 inhibitors. 
Compound E238 was selected since it showed good potential for synthetic optimization, and we 
also tested the binding of E238 to Bcl-2 and Bcl-xL proteins, and we were pleased to establish that 
no binding could be detected up to 100 µM (Table 2.5).  This data motivated us to proceed with 
the re-synthesis of E238 and further probe the proposed binding mode and provide additional 
structure-activity relationship (SAR) of this validated Mcl-1 hit compound. Our goal was to 
primarily examine the importance of the furan interaction with Arg263 and also produce 
derivatives that would probe the interactions with the Mcl-1 p2 binding pocket. It should be noted 
that Resynthesized E238 compound showed the same behavior as the commercial sources in all 
binding assays. The inhibition of all synthesized compounds was tested using FP-assay and 
binding of selected active compounds was further investigated using SPR and TR-FRET 
experiments. 
 When replacing the furan with thiophene or phenyl rings, the inhibition of new compounds 
E309 and E323 to Mcl-1 was significantly decreased (Table 2.2). The main reason could be the 
orientation requirement of the hydrogen bond between Mcl-1 Arg 263 and the ligands. Compound 
E325, where the two furan rings were replaced with two pyridine rings, also did not show 
inhibition, indicating the importance of the proper hydrogen bond placement for the successful 










Table 2.2.Exploring the influence of substituting the two five-membered furan moieties R1 
and R2 in the initial hit compound E238. 
 
When analyzing the available Mcl-1 structural data, it can be established that its p2 binding pocket 
is relatively larger in volume compared to the other three pockets of the BH3 binding groove, 
therefore, to enhance the affinity against Mcl-1, we tried to introduce more hydrophobic moieties. 
Compounds E63 – E262 with various substitutions introduced to the phenyl end of the 
thioacetamide linker were synthesized to probe this change (Table 2.3).  Firstly, the para 
substitution on the benzene ring was explored. The added short alkyl group on the para position of 
the phenyl ring in compounds E63 (IC50 = 4.98±0.25 µM) and E215 (IC50 = 2.27±0.65 µM) 
showed improved affinity over E238. This improvement was shown to be dependent on the nature 
of the substitutions: when at the para position the methoxy or phenoxy groups were introduced in 






                    
 





SPR IC50  
  [µM]       




13.77±1.39 3.23±0.33 13.44±0.20 11.90±3.65 
E309 
  
>100 >25 >100 >100 
E323 
  
>20 >5 >100 N.D. 
E325 
  




Table 2.3.Measured Mcl-1 inhibition properties for the series of compounds that explore the 
















13.77±1.39 3.23±0.33 13.44±0.20 11.90±3.65 
E63 
 
4.98±0.25 1.17±0.06 14.25±2.01 5.53±1.77 
E215 
 
2.27±0.65 0.53±0.15 11.62±1.12 N.D. 
E225 
 
33.06±7.69 7.76±1.80 47.38±3.88 N.D. 
E357 
 
6.87±1.90 2.83±0.78 N.D. 8.97±3.79 
E326 
 
>100 >25 >100 >80 
E329 
 
>100 >25 >100 N.D. 
E217 
 
8.09±0.79 1.90±0.18 12.47±1.65 11.56±4.00 
E232 
 





2.52±0.59 0.59±0.14 4.21±0.39 5.12±1.46 
E229 
 
5.27±0.45 1.24±0.11 N.D. N.D. 
E221 
 
2.62±0.25 0.61±0.06 N.D. N.D. 
E305 
 
5.09±0.48 1.19±0.11 6.3±0.62 7.13±2.81 
E343 
 
2.71±0.44 0.64±0.10 5.3±2 4.02±1.69 
E263 
 
4.14±1.50 0.62±0.19 7.3±2.12 7.93±4.66 
E262 
 
4.40±0.45 1.03 ±0.11 1.94±0.67 12.73±4.50 
 
This indicated that introduction of polar oxygen reduces the binding activity. This was also 
confirmed when attaching amino group at the para position of the phenyl ring of E238, resulting 
in a complete loss of inhibition affinity in compounds E326, E329. Fluorine atom at the para 
position in E217 showed comparable inhibition to E238, and introduction of the additional phenyl 
or benzyl moiety at the para position in E232 or E346 respectively resulted in similar binding to 
E215, indicating that introduction of bulkier hydrophobic moieties does not significantly improve 
the binding for this class. Further investigation with introduced various bulkier substitutions in 
compounds from E229 to E262 were in line with this observation (Table 2.3).  
In the final series of compounds, we substituted the amide in E238 with a two carbon 
linker, yielding E245 with improved activity. Shortening of this linker length by one carbon in 
E244 slightly reduced activity and increasing the linker length in E284 preserved the activity. 
When the triazine ring was changed to the rigid fused quinoxaline ring in compounds E311 and 
E312, inhibition was abrogated, confirming that flexible smaller parts are crucial for successful 
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binding (Table 2.4). We performed competitive SPR and TR-FRET experiments and in most cases 
the results align nicely with the discussed SAR FP binding data.  
The selectivity profiles of the hit compound and several potent analogs, E305, E245, and 
E284 were determined against other members of the Bcl-2 family, namely Bcl-2 and Bcl-xL (Table 
2.5). All compounds showed selective binding against Mcl-1, as observed for the starting hit 
compound 20. Importantly, the new designed and synthesized compound had improved selectivity 
profile and did not show binding to Bcl-2 or Bcl-xL up to 100 µM. 
 
















































Table 2.5.Selectivity profile of E238 and other analogs. 
 
2.4.4 Using model cell lines to better understand the cellular activity of E305 
 
The activity of the apoptosis effectors Bak and Bax can be suppressed by multidomain anti-
apoptotic proteins such as Mcl-1. If cell death induction is specifically mediated by Mcl-1 protein, 
Bax or Bak would be required for release of cytochrome c and subsequent cell death. Bax and Bak 
are considered as major players in triggering apoptosis, and inhibitors of anti-apoptotic proteins 
(e.g. Mcl-1) are expected to induce cell death in a Bax/Bak-dependent manner.[59] In order to 
explore the mechanism of E305 cellular activity, we used murine embryonic fibroblasts (MEFs) 
wild-type (WT) and either Bax or Bak knockout in addition to Bax/Bak double knockout (DKO). 
Treating WT MEFs with E305 for 15 h results in a dose-dependent increase of cell death, detected 
by propidium iodide (PI) as shown of (Figure 2.4a). The knockout of either or both Bax and Bak 
rescued the cells from the effect of E305, indicating that the presence of both Bax and Bak is 
necessary to induce cell death using our Mcl-1 inhibitor.   
The target specificity of this class of inhibitors was further confirmed using the reported retroviral 
transduced lymphoma cells isolated from Eμ-myc transgenic mice, which differ only in their 
expression of anti-apoptotic Bcl-2 family proteins. [60] Lymphoma cells overexpressing Mcl-1, 
Bcl-2 or Bcl-xL were treated with increasing concentrations of E305 for 15 h and the cell viability 
was determined by flow cytometry using the fluorescent reactive dye (LIVE/DEAD fixable violet 
stain kit).  Eµ-myc cells overexpressing Mcl-1 showed sensitivity to E305 in a concentration-
dependent manner. On the contrary, E305 was significantly less effective against Eµ-myc cells 
overexpressing Bcl-2 or Bcl-xL (Figure 2.4b). This confirms that E305 selectively binds to Mcl-1 
with no effect on Bcl-2 and Bcl-xL, which is consistent with the selectivity profile based on the 




Compounds Mcl-1 Mcl-1 Bcl-2 Bcl-2 Bcl-xL Bcl-xL
IC50± SD (µM) K i ± SD (µM) IC50± SD (µM) K i ± SD (µM) IC50± SD (µM) K i ± SD (µM)
E238 13.77±1.39 3.23±0.33 >100 >23.6 >100 >20
E305 5.09±0.48 1.19±0.11 >100 >23.6 >100 >20
E245 1.50±0.29 0.35±0.07 >100 >23.6 >100 >20







Figure 2.4.Mcl-1 inhibitor E305 induce Bax/Bak-dependent cell death to MEFS and on-
target Mcl-1 cell activity. (A) MEFs were treated for 15 h with increasing concentrations of E305. 
Cell viability was assessed using propidium iodide staining detected with flow cytometry. (*) is p 
< 0.05. (B) Cells were treated for 15 h with increasing concentrations of E305. The percentage of 
dead cells was calculated using LIVE/DEAD fixable violet dead cell stain (ViVID) and detected 
with flow cytometry. (*) is p < 0.05 
 
2.5  Conclusions 
 
 Mcl-1 is a validated target of importance in the progression of cancer and resistance of 
cancer cells to chemotherapies and radiation. It has been shown that for the apoptosis to occur, 
both arms of the anti-apoptotic proteins (Mcl-1 and Bcl-2/Bcl-xL) need to be neutralized.[61, 62] 
In this article, we have identified Mcl-1 inhibitors with novel scaffolds using results from the two 
previously reported HTS campaigns (AID: 1417 and 1418) deposited into PubChem’s BioAssay 
Database. These HTS assays were conducted to experimentally screen a large database of 102,255 
compounds in an attempt to discover small molecular inhibitors that disrupt the interaction 
between Mcl-1 protein and its binding partners: Noxa (HTS AID: 1417), a specific Mcl-1 binding 
BH3-only protein that exhibits selectivity to Bcl-2 family proteins; and Bid (HTS AID: 1418), a 
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broad acting BH-3 only protein that binds Mcl-1 as well as other anti-apoptotic proteins, including 
Bcl-2 and Bcl-xL. 
After analyzing the docking poses of 1214 hits and identifying 67 compounds that mimic 
at least two conserved interactions that BH3 peptides have with the Mcl-1 protein, we purchased 
37 compounds. These compounds were then fully characterized with different biochemical and 
biophysical methods to validate their binding to the Mcl-1 protein. Among the most potent 
identified compounds, 20 new chemical scaffolds were confirmed as true binders to Mcl-1. To 
further develop the medicinal chemistry of these validated hits, SAR of the experimentally 
confirmed hit 20 (E238) was synthetically elaborated followed by selectivity and cell-based 
studies to gain more insight into this class of Mcl-1 inhibitors.  
 Overall, this approach aims to highlight the advantages of integrating the structure-based 
searching strategy with experimental methods for analyzing available results deposited in the 
PubChem’s BioAssay Database and as such represents a useful tool for identifying the most 
promising leads for the purpose of drug discovery. In addition, synthetic and cell-based elaboration 
of the selected validated hit will also be highlighted showing the exemplary next step in the drug 
discovery pipeline. This study and presented approach will guide the drug discovery community, 
especially those who do not have immediate access to the HTS facilities, on how to obtain valuable 
hits for further medicinal chemistry or chemical biology purposes by using the public resource of 
PubChem’s BioAssay database.  
 In addition, we have successfully explored SAR of one discovered Mcl-1 hit compound 
E238 with the 5,6-difuran-2-yl-1,2,4-triazine core by synthesizing several novel derivatives. In 
this phase we exemplified the succeeding step in the drug discovery pipeline after validation of 
the hit compounds. The hit compound E238 was chosen since it also showed selectivity to Mcl-1 
versus Bcl-2 and Bcl-xL. The SAR studies led to the development of Mcl-1 inhibitors that were 
ten times more potent, e.g. E284. Selected cell-based experiments conducted using MEFs and Eµ-
myc lymphoma model cell lines showed that the optimized compound E305 can selectively target 
the Mcl-1 protein and induce selective Bax- and Bak-dependent cell death. These synthesized 
compounds outline that hit compound 20 uncovered a promising class of compounds, paving the 
way to efficient Mcl-1 inhibitors for the treatment of complex tumors. 
 In this study, we tried to depict the added value of the utilization of PubChem’s BioAssay 
Database in the hit identification process for the drug discovery community. These datasets 
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provide a vast amount of bioactivity results from hundreds of preformed HTS programs. HTS is a 
valuable tool to identify active compounds against a particular target and is a starting point for the 
medicinal chemistry community. However, HTS is mostly out of reach for standard utilization in 
smaller academic groups. This workflow shows, for academics as well as researchers in industry, 
an example of taking advantage of PubChem’s BioAssay Database, with the integration of 
computational and experimental pipelines to screen these libraries of potential hits, identify and 
validate real binders for a particular target, and further develop them using medicinal chemistry. 
 
 
2.6  Materials and methods 
 
High throughput screening compounds 
37 compounds were purchased from Sigma-Aldrich (1), SPECS (2-4,22,23), Princeton 
biomolecular research (5-9, 21,24-31), Interbioscreen (10-12,32-34), and Enamine (13-19,35-37). 
Molecular Modeling 
The chemical structures of the 1384 compounds from the two performed HTS campaigns, AIDs 
1417 and 1418, were downloaded from PubChem’s Bioassay database as two sdf files. After 
removing 170 duplicated compounds, LigPrep 2.5 of the Schrödinger suite was employed to 
convert them into 3D structures.[63] Glide 5.6 SP of the Schrödinger suite was used to dock the 
remaining 1214 compounds into the Mcl-1 active site.[64, 65] The PDB ID of the employed Mcl-
1 structure is 2NLA, which also contains bound BH3-only peptide Noxa. At the same time, 
Schrödinger’s IFD was also employed for the docking studies, to consider the flexibility of the 
Mcl-1 protein. Schrödinger’s IFD predicts ligand binding modes and concomitant structural 
changes in the protein by combining Glide (the docking program of Schrödinger) and the 
refinement module in Prime (the protein structure prediction program of Schrödinger). Its main 
application is to generate an accurate complex structure for a ligand known to be active but that 
cannot be docked in a rigid structure of the receptor. IFD was used in our study because it 
incorporates protein flexibility as well as ligand flexibility, which is important for accurate 
docking, especially when the protein is showing increased levels of flexibility experimentally. The 
docking protocol that was used for the IFD studies consisted of the following steps: (1) Constrained 
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minimization of the protein with an RMSD cutoff of 0.18 Å. (2) Initial Glide docking of the ligand 
using a softened potential (Van der Waals radii scaling). (3) One round of Prime side-chain 
prediction for each protein/ligand complex, on residues within defined distance of any ligand pose. 
(4) Prime minimization of the same set of residues and the ligand for each protein/ligand complex 
pose. (5) Glide re-docking of each protein/ligand complex structure within a specified energy of 
the lowest energy structure. (6) Estimation of the binding energy (IFDScore) for each output pose. 
In our study, all docking calculations were run in the extra precision (XP) mode of Glide. During 
both docking studies, the center of the grid box of Mcl-1 was defined by Val 249 (in h1), Phe 270 
(in h2), Val 220 (in h3/h4) and Val 216 (in h4). The size of the grid box was set to 15 Å. Default 
values were used for all other parameters. 
Protein purification  
His-tagged proteins containing Human Mcl-1 (residues 171–323), Bcl-2 (The isoform 2 construct 
of the human Bcl-2), and Bcl-xL (Human Bcl-xL protein, which has an internal deletion for the 
45-85 amino acid residues and a C-terminal truncation for the amino acid residues 212-233) were 
expressed from the pHis-TEV vector (a modified pET vector) in E. coli BL21 (DE3) cells. Cells 
were grown at 37 ºC in 2×YT containing antibiotics to an OD600 density of 1.5, 1, and 0.8 for 
Mcl-1, Bcl-xL, and Bcl-2 respectively. Protein expression was induced by 0.4 mM IPTG at 20 ºC 
overnight. Cells were lysed in 20 mM HEPES pH 7.5, 200 mM NaCl, 0.1% βME, and 40 µL of 
Leupeptin/Aprotinin (Mcl-1), 25mM Tris pH 8.5, 200mM NaCl (Bcl-2), and 50mM Tris pH 7.5, 
200 mM NaCl (Bcl-xL). All proteins were purified from the soluble fraction using Ni-NTA resin 
(QIAGEN), following the manufacturer’s instructions. For purification of TEV-cleaved protein, 
the amino terminal His tag was cleaved by incubation with TEV protease and the protein was 
further purified by anion exchange (Source Q) and gel filtration chromatography (Superdex 75, 
Amersham Biosciences) in 20mM HEPES pH 7.0, 50 mM NaCl (Mcl-1), 25 mM Tris pH 8.5, 150 
mM NaCl, 0.1% βME (Bcl-2), and 20 mM Tris pH 7.5, 150 mM NaCl, 0.1% βME (Bcl-xL). His-
tagged Mcl-1 protein was used for TR-FRET assay and HSQC-NMR. His-TEV cleaved Mcl-1, 





Fluorescence polarization based binding assay 
FP-based binding assays were developed and optimized to determine the binding affinities of Bcl-
2 family protein inhibitors to the recombinant Mcl-1, Bcl-2, and Bcl-xL proteins. Fluorescein 
tagged Bid peptide (Flu-Bid) was used as a fluorescent probe in the FP-based binding assays. One 
fluorescein tagged Bid peptide named Flu-Bid (generously provided by Dr. Shaomeng Wang) was 
labeled with fluorescein on the N-terminus of the BH3 peptide (79-99), while the second tracer 
was purchased from Abgent (Catalog # SP2121a), named FAM-Bid, where the BH3 peptide (80-
99) is labeled with 5-FAM. Their Kd values were determined for Mcl-1, Bcl-2, and Bcl-xL with a 
fixed concentration of the tracer (2 nM of Flu-Bid and FAM-Bid) and different concentrations of 
the tested proteins, in a final volume of 125 µL in the assay buffer (20 mM phosphate pH 7.4, 50 
mM NaCl, 1 mM EDTA and 0.05% Pluronic F68). Plates were mixed and incubated at room 
temperature for 3 hours and the polarization values in millipolarization units (mP) were measured 
at an excitation wavelength of 485 nm and an emission wavelength of 530 nm. Equilibrium 
dissociation constants (Kd) were calculated by fitting the sigmoidal dose-dependent FP increases 
as a function of protein concentrations using Graphpad Prism 6.0 software (Graphpad Software). 
Based upon analysis of the dynamic ranges for the signals and their Kd values, Flu-Bid was selected 
as the tracer in the Mcl-1 competitive binding assays, while FAM-Bid was selected as the tracer 
for Bcl-2 and Bcl-xL.  In our saturation experiments, the Kd value of Flu-Bid with Mcl-1 was 3.04 
± 0.06 nM, and the Kd values of FAM-Bid with Bcl-2 was 18.44 ± 1.40 nM, and to Bcl-xL was 
20.04 ± 2.34 nM respectively. For testing of purchased compounds based on the Kd values, the 
concentrations of the proteins used in the competitive binding experiments were 20 nM of Mcl-1 
with Flu-Bid in assay buffer (50 mM Tris pH 7.4, 50 mM NaCl and 0.005% Tween 20). For testing 
the synthesized library of compounds based on compound 47, we used 10 nM of Mcl-1 with Flu-
Bid for Mcl-1, and 60 nM and 80 nM of FAM-Bid with Bcl-2 and Bcl-xL respectively, in assay 
buffer (20 mM potassium phosphate, pH 7.5; 50 mM NaCl, 1 mM EDTA and 0.05% Pluronic 
F68). The fluorescent probes, Flu-Bid and FAM-Bid were fixed at 2 nM for all assays. 5 μL of the 
tested compound in DMSO and 120 μL of protein/probe complex in the assay buffer were added 
to assay plates (Corning #3792), incubated at room temperature for 3 h, and the polarization values 
(mP) were measured at an excitation wavelength at 485 nm and an emission wavelength at 530 
nm using the plate reader Synergy H1 Hybrid, BioTek. IC50 values were determined by nonlinear 
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regression fitting of the competition curves (GraphPad Prism 6.0 Software). The Ki values were 
calculated as described previously. 
Surface plasmon resonance (SPR) based binding assay 
 
The solution competitive SPR-based assay was performed on Biacore 2000. N terminal biotin-
labeled Bim BH3 peptide (141–166 amino acids) was immobilized on streptavidin (SA) chip 
giving a density of 800 RU (Response Units). The preincubated Mcl-1 protein (20 nM), with tested 
small-molecule inhibitors for at least 30 min, was injected over the surfaces of the chip with two 
minutes of association and one minute of dissociation using assay buffer HBS-P (GE, 
#BR100368). Response units were measured at 15 s in the dissociation phase, and binding was 
calculated by subtracting the control surface (Fc1) signal from the surfaces with immobilized 
biotin-labeled Bim BH3. IC50 values were determined by nonlinear least-squares analysis using 
GraphPad Prism 6.0 software. 
 
Time-resolved fluorescence energy transfer (TR-FRET) binding assay 
 
TR-FRET was performed using black 384-well plates in an Envision Multilabel plate reader 
(PerkinElmer Life Sciences). To each well, a mixture of 10 nM Bid-Dy647 peptide (79-99), 10 
nM Mcl-1 protein, and Eu-W1024 anti-6xHis antibody (1 nM, PerkinElmer) were added to a final 
volume of 25 μL in the assay buffer (20 mM potassium phosphate, pH 7.5; 50 mM NaCl, 1 3 
EDTA and 0.05% Pluronic F68). The TR-FRET signals were measured with an Envision 
Multilabel plate reader after 2 h of incubation, (Ex 337 nM, Em1 655 nM and Em2 615 nM) and 
expressed as FRET signal ratio (F665nm / F615nm * 104) 
 
1H, 15N HSQC NMR  
 
NMR studies were performed as previously described.[43] In brief, for 1H,15N -HSQC NMR 
studies, 15N-labeled Mcl-1 proteins were prepared and purified using the same protocol as for 
unlabeled protein, with the exception that the bacteria were grown on M9 minimal media supported 
with 1 g/L of (15NH4)2SO4. Protein samples were prepared in a 20 mM sodium phosphate, 150 mM 
NaCl and 1 mM DTT solution at pH 7 in 7% D2O. The binding mode of compounds was 
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characterized with a solution of uniformly 15N-labeled Mcl-1 (75μM) in the absence and presence 
of added compounds (in 1 or 6% final DMSO), with the indicated molar ratio concentrations. Total 
volume of each sample was 150 μL, and samples were prepared in Bruker tubes (Bruker, # 
Z117724). All Spectra were acquired at 30 oC on a Bruker 600 MHz NMR spectrometer equipped 
with a cryogenic probe, processed using Bruker TopSpin and rNMR[66], and were analyzed with 
Sparky.[67] Plots of chemical shift changes were calculated as ((Δ1H ppm)2 + (0.2(Δ15N 
ppm))2)0.5 of Mcl-1 amide upon addition of compound. The absence of a bar in a chemical shift 
plot indicates no chemical shift difference, or the presence of a proline or residue that is overlapped 
or not assigned. 
 
Cell viability assays 
 
MEFs cells, wild type, Bax knock out, Bak knock out, Bax/Bak double knock out, and Mcl-1 
knock out were gifts from Dr. Shaomeng Wang at the University of Michigan and were cultured 
in DMEM (Life Technologies), supplemented with 10% fetal bovine serum (FBS) (Thermo 
Scientific HyClone) and 1% Penicillin/streptomycin solution (Life Technologies). The retroviral 
transduced lymphoma cells isolated from Eμ-myc transgenic mice were gifts from Ricky W. 
Johnstone at the University of Melbourne, Melbourne, Australia and cultured as previously 
described. 80 PANC-1 was obtained from the American Type Culture Collection (ATCC). The 
cells were cultured in DMEM (Life Technologies), supplemented with 10% FBS and 1% 
Penicillin/streptomycin solution. MEFs cells were seeded in 24-well plates at 0.5 x 105 cells/well, 
left to adhere for 5 hours and then treated for 15 hours with increasing concentrations of the 
compounds. The cells were harvested, washed with phosphate-buffered saline (PBS), and stained 
with 0.025 mg/ml propidium iodide (MP Biomedicals). The percentage of propidium iodide 
positive population was determined by flow cytometry and calculated using WinList 3.0. The Mcl-
1, Bcl-2, and Bcl-xL retroviral transduced lymphoma Eμ-myc cells were seeded in 12-well plates 
at 0.5 x 106 cells/well. They were treated with different concentrations of tested compounds for 16 
hours. The cells were harvested and stained with violet LIVE/DEAD Fixable Dead Cell Stain Kit 
(Invitrogen) according to manufacturer's protocol.  The percentage of fluorescent positive cells 
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Figure 2.5.Predicted binding poses and the HSQC NMR analysis of the confirmed 




Figure 2.6.Predicted binding poses and the HSQC NMR analysis of the confirmed 




Figure 2.7.Predicted binding poses and the HSQC NMR analysis of the confirmed 
compounds 12,13,17,18, and 19. 
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CHAPTER 3  




 A drug discovery program usually initiates because of the need to develop interventions 
against a certain disease or clinical condition. The first step is often performed in academia where 
a hypothesis is formulated stating that the inhibition or activation of a certain target protein, gene, 
RNA, or pathway will generate a therapeutic effect. Target identification and validation is a crucial 
step in the road to drug discovery. [1] The target has to meet an unmet medical need, and to be 
safe enough that there is an established relationship with the disease without a mechanism-based 
side effect. The most important characteristic of a target is druggability; the capability to develop 
small molecules or biologicals that can bind to the target and trigger the desired biological and 
therapeutic response. The second step is identification of hits through various methods of screening 
assays. The hits are compounds that show activity towards the target and are confirmed to bind to 
the target in a dose dependent manner. High throughput screening (HTS) is one of the approaches 
used in hit identification. Several approaches of HTS have been described in chapter 2, from 
libraries of small molecules to fragments or using pharmacophores or structure-based virtual 
screening of compound libraries. HTS can be cell-based, where a certain outcome that correlates 
with modulating the target is detected when cells are treated with an active compound. The third 
step of the drug discovery process is identifying a lead compound based on the hit generated from 
HTS step. The objective is to refine the hits to generate lead compounds with more potent and 
selective affinity to the target, as well as good physicochemical properties, to test their in vivo 
efficacy. Once a compound reaches that stage, it undergoes PK/PD, toxicity, metabolic stability, 
and chemical stability studies.
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 With the collected information about the compound, a drug candidate profile is submitted to 
regulator authorities for initiating clinical studies on human subjects. 
 
3.2 Structure-based design approach to develop protein-protein interactions modulators 
 Protein-protein interactions (PPIs) are involved in various cellular processes from signaling 
pathways of cells to host-pathogen recognition. We now have a vast knowledge of structural data 
for thousands of these PPIs through X-ray crystallography or nuclear magnetic resonance (NMR). 
The atomic structures of thousands of protein complexes have been solved by X-ray 
crystallography and nuclear magnetic resonance spectroscopy.[2] This knowledge enhances our 
understanding of PPI interfaces and opens the door for computationally designing novel 
modulators for these PPIs. With the availability of structure of the targeted protein– protein 
complex or isolated protein partners, inhibitors can be identified using high-throughput docking 
[3, 4] or pharmacophore models.[5, 6] The protein structure can be further examined to identify 
druggable pockets for rigorous medicinal chemistry efforts.[7] Consequently, success in 
developing PPI inhibitors (PPIIs) will rely mainly on the use of computer-aided drug design to 
guide the high-throughput screening (HTS) campaigns as well as the optimization of hits emerging 
from these studies. With the improvements in docking algorithms and scoring functions, 
developing of PPII is still a challenging task.[8] One of the major obstacle is not accounting for 
protein flexibility in docking. However, this can be solved using induced fit docking or using a 
collection of conformations of the targeted protein. Several small-molecule PPIIs were developed 
using structure-based drug design such as inhibitors of Bcl-2, XIAP and MDM2. [9-11]. These 
success stories are good encouragement to apply structure-based drug design in targeting the anti-
apoptotic protein Mcl-1 
 
3.3 Results 
3.3.1 Structure based design of novel Mcl-1 inhibitors based on validated HTS hit   
 
 Employing a high throughput screening approach, several novel chemical classes were 
identified as Mcl-1 inhibitors.[12]  Cluster analysis revealed different clusters of compounds 
including a chemical class with 5,6-difuran-2-yl-1,2,4-triazine core structure. The hit compound 
E238 (Figure 3.1a), was resynthesized and its binding to Mcl-1 was confirmed with the IC50 value 
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of 13.8 ± 1.4 µM (Ki = 3.2 ± 0.3 µM) in the fluorescence polarization (FP) assay and TR-FRET 
based assay (IC50 value of 11.9 ± 3.7 µM) using a Bid BH3 peptide as a fluorescent probe. The 
direct and specific binding of E238 to the Mcl-1 protein was confirmed with the HSQC NMR 
spectroscopy and the obtained HSQC spectra showed concentration-dependent perturbations of 
the backbone amide residues (Figure 3.1b). Overall, the analysis of the HSQC chemical shift 
changes of the compound E238 in complex with Mcl-1 showed that the E238 compound affects 
the residues forming the Mcl-1 BH3-binding groove, and provided conclusive evidence that it 
binds to the Mcl-1 protein at the same site where the conserved BH3 peptides interact with the 
Mcl-1 protein. These results also corroborated the predicted binding model of E238 in complex 
with Mcl-1, which revealed that the compound forms hydrogen bonds between the oxygen atom 
of one furan ring and a nitrogen from the triazine core structure of E238 and the Arg263 residue 
of Mcl-1, mimicking the conserved aspartate in pro-apoptotic proteins (Figure 3.1c). The phenyl 
ring of the E238 projects into the Mcl-1 hydrophobic pocket 2 (p2), mimicking the conserved 
hydrophobic residue Leu in the BH3 binding motif of BH3-only pro-apoptotic proteins.[13] The 
second furan ring sits over the p3 pocket and displays weak hydrophobic interaction with the 
Thr266. The sulfur-amide chain of E238 did not show direct interactions with Mcl-1, playing the 
role of a linker.  
 As stated in Chapter 2, structure activity relationship (SAR) studies of a synthetic library, 
with more than 50 analogs based on the E238 validated hit, showed the essential role of one furan 
ring which forms the conserved hydrogen bond with Arg263 of Mcl-1 based on the predicted 
binding model (Figure 3.1c). Decorating the phenyl ring with hydrophobic substituents led to 
improvement of the binding affinity consistent with the binding model, showing that the phenyl 
ring is embedded in the p2 hydrophobic pocket. Although the binding affinity of novel analogs 
was improved by 10-folds, the difuran-triazine core limits the synthetic possibilities for further 
modification. Thus, based on the SAR findings, compound 368LM was de-novo designed (Figure 
3.1d), where one furan ring was replaced with carboxylate moiety to preserve the hydrogen bond. 
Flexible methylene linker was introduced instead of the amide and the other furan ring was 
replaced with phenylsulfonamide to further explore and improve hydrophobic interactions with 
the p2 and p4 pockets, respectively. Interestingly, this compound binds to Mcl-1 with a slightly 
improved binding affinity (Ki = 1.2 ± 0.2 µM) compared to E238, and shows significant chemical 
shift perturbations in 15N-HSQC NMR spectrum indicative of binding to the Mcl-1 BH3-binding 
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groove (Figure 3.1e). The predicted binding model of 368LM in the complex with Mcl-1 revealed 
that the phenethylthio moiety occupies the p2 pocket and has hydrophobic interactions with 
Leu267, Val253, Val243 and Leu235 residues (Figure 3.1f). The proposed interactions were 
confirmed with the HSQC NMR experiments, in which these residues showed significant chemical 
shift perturbations (Figure 3.1e). The carboxylic group formed a hydrogen bond with the Arg263, 
mimicking the conserved aspartate in pro-apoptotic proteins, similar to the interactions observed 
with the furan moiety present in the E238 structure. Indeed, the HCQS NMR spectrum of 
368LM/Mcl-1 complex showed that Arg263 has a significant chemical shift. The 
benzenesulfonamide was placed above the p3 pocket and showed weak interactions with Thr266, 
Ala277 and Phe228 (Figure 3.1f). Taken together, in silico docking and HSQC NMR studies 
provided conclusive evidence that 368LM binds to the BH3-binding groove of Mcl-1 protein.  
 
3.3.2 SAR investigation of new class of Mcl-1 inhibitors 
 
 The first series of compounds was synthesized to explore the position and importance of 
the R1, benzene sulfonamide, and R2, phenethylthio, substituents on the Mcl-1 binding affinity 
(Table 3.1). Deletion of the benzene sulfonamide substituent in 416LM didn’t affect the binding 
affinity and gave very similar Ki value of 1.13±0.19 µM to the lead compound 368LM. However, 
deletion of the R2 substitution in 455LM resulted in a 50-fold decrease of binding affinity, 
demonstrating that phenethylthio significantly contributes to the binding potency to Mcl-1. These 
findings are consistent with the predicted binding model showing that phenethylthio is placed in 




Figure 3.1.Binding models of E238 and 368LM in the BH3 binding pocket of Mcl-1 based on 
HSQC NMR data. (A) and (D) Chemical structures; (B) and (E) Obtained HSQC NMR chemical 
shift perturbations; (C) and (F) Predicted binding poses of E238 and designed 368LM compounds 
in the Mcl-1 binding site (PDB used for binding mode prediction: 4HW2) 
The position of the phenethylthio group also plays an important role in binding to Mcl-1, as its 
introduction at the para position relative to the carboxylic group in 702LL displayed 9-fold 
decrease in potency (Ki = 9.3 ± 1.0 µM) compared to 368LM. One carbon reduction of the aliphatic 
chain at the R2 position in 392LM gave 2-fold decrease with Ki of 2.3 ± 0.2 µM. Replacing the 
sulfur atom with the amino group also led to 9-fold reduction in the binding potency (Ki = 8.7 ± 




Table 3.1.Exploring the SAR of substituted benzoic acid scaffold 
 















































































Changing the sulfonamide linker at the R1 position to the amide linker in compound 
364LM gave similar binding affinity in comparison with 368LM (Ki = 2.4±0.1 µM). Based on 
these results, we synthesized a series of Mcl-1 inhibitors, 387LM-460LM, where the R2 
phenethylthio group was fixed at the meta position relative to the carboxylic group, and studied 
the SAR of the substituents at the R1 position (Table 3.2). Bioisosteric replacement of the R1 
benzene with the thiophene moiety (387LM) gave a similar binding affinity. Introducing small 
hydrophobic substituents at the benzene ring, including a chlorine or bromine atom in ortho, meta 
and para positions, led to 5-fold improvement over the 368LM (384LM with Ki = 0.3 ± 0.1 µM 
and 389LM (Ki = 0.4 ± 0.1 µM). Introducing a larger lipophilic moiety resulted in further 
improvement of the binding affinity (382LM to 376LM).  
 The replacement of benzene at R1 with bulkier naphthalene resulted in compound 382LM 
with the Ki = 0.2 ± 0.01 µM. Based on our previously reported series of Mcl-1 inhibitors [14] 
biphenyl and phenoxy-phenyl moieties proved again to be favourable substituents for targeting 
these PPIs and led to 13-fold (378LM Ki = 0.09 ± 0.02 µM) and 12-fold (376LM Ki = 0.10 ± 0.02 
µM) improvements in binding affinity. Replacing the distal phenyl ring with saturated cyclohexyl 
group (418LM Ki = 0.04 ± 0.01 µM) or introducing a chlorine in para position (380LM Ki = 0.03 
± 0.003 µM), the binding affinity was significantly (34-fold) improved, in comparison with the hit 
compound 368LM. To investigate the importance of the adjacent phenyl ring and at the same time 
to improve the physicochemical properties of the inhibitor series, especially in terms of solubility, 
this phenyl ring in 378LM was replaced with the heterocyclic piperazine moiety. Resulting 
compound 396LM showed 6-fold decreased binding with Ki of 0.6 ± 0.1 µM. Introducing the 
methylene spacer between the piperazine moiety and the phenyl substituent in compound 414LM 
and para-flouro-phenyl derivative, 462LM, showed similar binding affinity as the parent 396LM 
compound. To determine the contribution of the phenethylthio group for the Mcl-1 binding, 
compounds 453LM and 460LM were synthesized. Both compounds showed significantly (about 
80-fold) reduced binding affinity in comparison with corresponding compounds, clearly 







Table 3.2.SAR of the phenethylthio benzoic acid derivatives for binding to Mcl-1 determined 
by FP and for selected compounds with TR-FRET binding assays. 
 



















































































































































































3.3.3 Structural studies of novel Mcl-1 inhibitors 
 
 To better understand the key binding elements for novel Mcl-1 inhibitors, co-crystal 
structures of 382LM, 396LM, and 462LM bound to Mcl-1 were obtained at 2.74, 2.55, and 2.10   
Å respectively. Overall, all Mcl-1 structures with bound inhibitors aligned nicely with the 
previously reported Mcl-1 structures. The alignment of new co-crystal structures with the available 
apo-MBP-Mcl-1 (PDB: 4WMS [15]) is shown in Figure 3.2a. The structures were aligned to 
462LM using the SSM algorithm in Coot [16] and the resulting root mean square deviations for 
each structural pair is 1.1725 Å for apo, 0.758 Å for 382LM, and 0.899 Å for 396LM. Mcl-1 loop 
254-256 is disordered in the apo structure, leading to its larger deviation in this area and the 
aberrant termini in the BH3 binding site. The most prominent change vs. the apo MCl-1 structure 
was the minor repositioning of the α4-helix relative to the apo-Mcl-1 structure. This structural 
movement was observed before for the Mcl-1 ligands, and helps to accommodate the ligand in the 
hydrophobic (p2) pocket the top of Mcl-1 α4 helix closer to the ligand.[17] As expected, the acid 










and mimicked the hydrogen bond interaction observed with this residue and the pro-apoptotic 
proteins of Bim and Noxa.  
 
Figure 3.2. Co-crystal structures of 382LM, 496LM and 462LM with Mcl-1. (A) Overlay of 
the Cα traces of 382LM (green), 396 (blue) and 462LM (orange) and apo-MBP-Mcl-1, PDB ID 
4WMS, (gray) depicting movement in the α4-helix (circled in red) upon ligand binding. Loop 254-
256 is disordered in the apo structure leading to its larger deviation in this area and the aberrant 
termini in the BH3 binding site. X-ray crystallography complex of several inhibitors with Mcl-1 
protein: (B) 382LM; (C) 396LM and (D) 462LM. The side chains of selected interacting Mcl-1 
residues are labeled. 
 
 In the 382LM co-crystal structure, four Mcl-1 protein molecules occupy a single unit cell. 
The 382LM molecule binds the Mcl-1 molecule in a U-shaped binding mode with the Arg263 
carboxylic group as the main anchoring interaction (Figure 3.2b). When fitting the 382LM ligand 
into the obtained electron density for the Omit electron density maps for all bound ligands 
(Appendix Figure 3.5), it was observed that the R2 phenethylthio moiety is pointing towards the 
p2 pocket interacting with the hydrophobic side chains of the Mcl-1 α3 helix (e.g. Met231), and 
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sulfur-containing side chain of Met250 (Figure 3.2b) on the Mcl-1 α4 helix, similarly as in the 
proposed binding model for the initially designed 368LM (Figure 3.1f). Some of the Mcl-1 
residues that were observed to form hydrophobic interactions with the ligand were Leu235, 
Met250, Val253, and Phe270.  
The Mcl-1 Met231 side chain residue was located in the conformation that closely 
resembles the reported three-dimensional structures of the complexes formed between Mcl-1 BH3 
peptides (e.g. Bim and Noxa), with less opened p3 pocket compared to some of the previously 
reported Mcl-1 inhibitor co-crystal structures.[15, 17-19] The compound’s 382LM R1 
naphthalene moiety is located on top of the P3 hydrophobic pocket, partially stabilized by the π- π 
stacking with the 382LM phenyl group as well as through hydrophobic interaction with Val254.  
 In the Mcl-1 structure containing 396LM, one Mcl-1 molecule is occupying a single unit 
cell. Interestingly, the 396LM compound is bound to the Mcl-1 BH3 binding site in a U-shaped 
flipped binding conformation in comparison to the bound 382LM compound (Figure 3.2c). In 
addition, the benzene core structure is less buried into the Mcl-1 binding site, occupying a different 
position compared to the Mcl-1 382LM structure. The compound’s R1 phenylpiperazine-
sulfonamido substituent is placed into the Mcl-1 p2 hydrophobic binding pocket and the attached 
phenyl moiety interacts with the side chains of Leu267, Val253 and Leu235, and Val231 through 
hydrophobic interactions. The R2 S-substituted ethylbenzene moiety is located on top of the Mcl-
1 α3 helix and interacts to some extent with the sulfur-containing side chain of Met231 as well as 
the side chain of Leu235. The folded conformation of 396LM is also partially stabilized by the π- 
π stacking of its two distal phenyl groups.  
 In the co-crystal structure with bound 462LM, similar to the complex structure with 
382LM, four Mcl-1 protein molecules occupied a single unit cell. In terms of molecule orientation, 
two pairs of Mcl-1 structures faced one another with the 462LM ligands occupying all available 
BH3 binding sites. Staking pairs of Mcl-1 molecules were observed in some previous x-ray 
experiments.[20] The 462LM ligand is also bound in the Mcl-1 BH3 binding site in a flipped 
folded conformation compared to the 382LM bound conformation. The R1 piperazine-containing 
substituent of 462LM interacts with the Mcl-1 p2 hydrophobic binding pocket and the attached 
terminal 4-fouoro phenyl moiety is placed deeper in the p2 binding site compared to bound 
382LM, forming hydrophobic interactions with the side chains of Phe270, Met250, and Leu290. 
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The R2 phenethylthio moiety is located on top of the Mcl-1 α3 helix and has hydrophobic 
interactions with the sulfur-containing side chain of Met231 as well as the side chain of Leu235 
and Val253 (Figure 3.2d). Due to close stacking of two interacting Mcl-1 molecules, the charged 
side chain of Arg233 from the adjacent Mcl-1 protein is able to interact with the 462LM compound 
bound to its neighboring Mcl-1 molecule and vice versa. These important structural findings 
indicate that the binding mode of these compounds depends on the nature of substitution 
introduced into the molecule. The different binding modes and orientation of investigated ligands 
demonstrate the complex nature of molecular recognition governing the binding of small 
molecules to Mcl-1 and the challenges that face structure-based design efforts. 
 
3.3.4 Structure-based optimization of Mcl-1 inhibitors 
 
 Encouraged by the binding potency and SAR studies of our compounds, we continued to 
further optimize their potency, guided by our x-ray co-crystal structures and the structural data 
available in the literature. Recent studies have reported indole carboxylic acid [17] and salicylate 
based [20] Mcl-1 inhibitors through fragment-based drug design (FBDD). To facilitate structure-
based design of our inhibitors and gain an understanding of the similarities and differences in the 
interactions of our series of compounds and reported inhibitors, we compared the co-crystal 
structure of 382LM with available Mcl-1/inhibitors complex crystal structures (PDB ID: 4OQ6, 
[20] and PDB ID: 4HW2).[17]  
Superposition of 382LM complex structure and the structure of the salicylate based compound 
bound to Mcl-1 [20] showed that these inhibitors have similar binding poses (Figure 3.3a). In both 
structures the core scaffolds, the benzene carboxylic functionalities of the 382LM and the 
salicylate moiety in reported compound 36 (PDB ID: 4OQ6), sit in almost the same position and 
in both cases the carboxylate forms hydrogen bonds with Arg263 of the Mcl-1 protein. The 
phenethylthio substituent from 382LM and the 4-propylphenyl moiety of 36 are also closely 
superimposed and both are directed into the p2 pocket, although the n-propyl moiety extends 
deeper into the pocket, making Van der Waals contact with the sidechains of Leu235 and Val249 
as was reported.[20] We observed the favorable overlap of analyzed co-crystal structures and, to 
take advantage of additional interactions found in compound 36, we investigated the replacement 
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of the phenethylthio substituent in 382LM by utilizing available SAR data. [20] The resulting 
compounds, 466LM, 468LM and 473LM, showed 2 to 4-fold improved binding over the 382LM. 
Further studies to test the optimum position of the distal trifluoromethyl-benzene and naphthalene 
substituent showed that the para positions of this functionality in 471LM (Ki = 59.3 ± 10.2 nM) 
and 475LM (Ki = 25.0 ± 5.9 nM) are favored over the ortho substitution present in the compounds 
468LM (Ki = 85.9 ± 6.8 nM) and 473LM (Ki = 68.1 ± 9.1 nM). Furthermore, 471LM and 475LM 
have 4- and 5-fold, respectively, improved binding affinity in comparison with 382LM, 
demonstrating that these substituents at R2 position are more favorable in comparison with the 
phenethylthio moiety. At the same time, the contribution of the naphthalene-2-sulfonamide to the 
Mcl-1 binding seems to be essential, as compound 469LM showed significant 96-fold decrease in 
binding affinity in comparison with 471LM. While analyzing the superimposed co-crystal 
structures of 382LM with an indole-based ligand (PDB ID: 4HW2), a conformational change of 
the Met231 side chain was observed (Fig. 3B).[17] In the complex structure of the indole-based 
ligand, the “open confirmation” of the Met231 side chain induced by the compound improved its 
interaction with the hydrophobic p3 pocket through interactions with Phe228, Phe270, and Met231 
residues. Fesik and co-workers, in their previously described series of inhibitors, have 
demonstrated that a substitution at the 6-position of the indole enhances the binding potency.[17-
19] Interestingly, in both Mcl-1 complexes with 382LM and the salicylate-based ligand, the 
Met231 side chain is in the “closed confirmation” (Figure 3.3a). Based on these observations, in 
the next optimization step we hypothesized that the binding affinity to Mcl-1 could be improved 
by introducing a substitution at the 4-position of the benzene carboxylic core. To test this 
hypothesis, we synthesized compounds 474LM and 476LM, where the iso-propyl group was 
introduced at the 4-position of the benzene core scaffold. Both compounds showed 2-fold 
improvement in their binding affinity confirmed with FP- and TR-FRET based assays in 
comparison with corresponding compounds, 471LM and 376LM respectively (Tables 3.2 and 
3.3). Subsequent combination of the described structure-based modifications, and introducing 
favorable substituents based on our SAR results of the phenylsulfonamido substituent, yielded the 
compounds 477LM (Ki = 24.8 ± 18.9 nM) and 480LM (Ki = 18.5 ± 1.8 µM) with improved 
binding. Based on our initial exploratory SAR of the designed compound 368LM (Table 3.1), the 
sulfonamide linker was replaced with a smaller and more flexible amide linker in molecules 
483LM and 487LM, providing most potent compounds in this series with the Ki values of 10 nM 
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(Table 3.3). Using surface plasmon resonance (SPR)-based competitive assay, the binding 
affinities of 483LM (IC50 = 29 ± 4 nM) and 487LM (IC50 47 ± 6 nM) were comparable to Noxa 
(IC50 = 28 ± 1 nM) in competing with Bim peptide. (Appendix Figure 3.6) 
 
Figure 3.3.Alignment of 382LM co-crystal structure with reported co-crystal structures and 
predicted binding mode of 483LM. (A) (left) Alignment of the 382LM Mcl-1 complex and 4OQ6 
Mcl-1 structure and (right) alignment of the 382LM Mcl-1 complex and 4HW2 Mcl-1 structure 
(B) Proposed binding mode of the 483LM structure in the Mcl-1 binding site (PDB: 4HW2). 
Arrow indicates that, several positions of the R2 substituent in the p4 binding site or its immediate 




To get more insights about the binding pose and interactions of 483LM, this compound was 
docked into the Mcl-1 binding site using the reported Mcl-1 structure, PDB ID: 4HW2 (Figure 
3.3c).[17] In the predicted binding model the R1 phenoxyphenyl substituent is directed deep into 
the p2 pocket forming hydrophobic interactions with neighboring residues Leu290, Met250, 
Val249, Phe270, and Leu267. As expected the carboxylic group interacts firmly with the side chain 
of Arg263. The R3 iso-propyl group of 483LM sits above the P3 binding pocket with weak 
hydrophobic interactions. Importantly, all top-ranked poses showed that the R2 benzyloxy-
trifluoromethyl benzene substituent is directed towards the p4 pocket, mimicking the interaction 
of the conserved hydrophobic Phe residue of the BIM BH3 peptide. To support the predicted 
binding pose of 483LM and quantify the contribution of its substituents, we synthesized several 
compounds. Synthesizing compound 511LM, which has only phenoxyphenyl-sulfonamido 
substituent in R1 position led to detrimental decrease of the binding to Mcl-1 protein with Ki of 21 
µM, clearly providing evidence of the importance of R2 and R3 substituents. To further gain 
information about the R2 substituent, since it is hard to exactly define its placement by the 
molecular docking studies, compounds 495LM and 496LM were synthesized where the position 
of ethoxy-trifluoromethyl benzene moiety was changed. Both compounds showed a 3-fold 
decrease in binding affinity, confirming that the para position in 483LM is most optimal for 
binding to Mcl-1, consistent with 471LM and 475LM (Table 3.3). 491LM, derivative of 483LM, 
where the cyclopropyl substituent was introduced at the R3 position, displayed comparable 
inhibition. The necessity of the conserved electrostatic and hydrogen bond of carboxylic 
interaction with Arg263 was assayed by synthesizing 486LM, methyl ester of the potent 
compound 483LM, which did not show binding to Mcl-1 up to 100 µM. Importantly, for several 
synthesized compounds presented in Tables 2 and 3, the Mcl-1 binding was studied with the (TR-





Table 3.3.SAR of the second-generation benzoic acid derivatives for binding to Mcl-1 
determined by FP and for selected compounds with TR-FRET binding assays. 
 

































































































































































































































































3.3.5 Selectivity Profile 
 
The selectivity was determined against two other Bcl-2 anti-apoptotic proteins (Bcl-2 and Bcl-xL) 
using competitive FP-based assays optimized for each protein.  Selected analogs were tested 
and Ki values were calculated using previously developed equations (Table 3.4).[21] The most 
potent inhibitor 483LM shows high selectivity in binding to Mcl-1, at least 100 - and 800-folds 
compared to Bcl-2 and Bcl-xL, respectively. Interestingly, compounds 477LM and 480LM, which 
have sulfonamide versus amide linkers in corresponding 483LM and 487LM, show decreased 
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selectivity profile, 8 – and 20-fold less binding to Bcl-2. These results indicate that the amide 
linkers in 483LM and 487LM might be important for selective binding profile (Appendix Figure 
3.7).  
 
Table 3.4.Selectivity of selected inhibitors against Bcl-2 anti-apoptotic proteins. 
Compounds Mcl-1 Bcl-2 Bcl-xL 
  Ki ± SD (µM) Ki ± SD (µM) Ki ± SD (µM) 
E238 3.230±0.327 >25 >20 
368LM 1.166±0.158 >25 >20 
382LM 0.243±0.014 5.585±0.007 5.208±1.141 
396LM 0.582±0.062 15.660±0.014 6.170±0.928 
462LM 0.561±0.049 >25 >20 
477LM 0.025±0.018 0.210±0.050 >3 
480LM 0.019±0.002 0.435±0.134 >3 
483LM 0.010±0.001 >1 >3 
487LM 0.009 ±0.002 >1 >3 
491LM 0.009±0.001 >1 >3 
486LM >25 >25 >20 
 
3.3.6 Pulldown Experiment 
 
To confirm the binding of novel inhibitors to endogenous Mcl-1, we employed a pull-down 
assay using biotin-labeled Noxa (BL-Noxa) and whole cell lysate from the human breast cancer 
cell line 2LMP. As shown in Figure 3.4a, Mcl-1 was pulled down by BL-Noxa and, as was 
expected, the Bim BH3 peptide disrupted the interaction between BL-Noxa and Mcl-1. Pre-
incubation with 483LM and 491LM resulted in dose-dependently blocking the binding of BL-
Noxa to Mcl-1, with 483LM disrupting 50% of the Mcl-1/Noxa interactions at 1 μM. Compound 
486, which has the same chemical scaffold but does not bind to Mcl-1 and serves as a negative 
control, did not disrupt the interactions up to 40 µM. 382LM completely blocked the interaction 
at higher concentration, 100 µM, consistent with its lower binding affinity. These results further 
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demonstrate that these inhibitors can recognize and specifically bind to the BH3 binding groove 
of endogenous Mcl-1 protein.  
 
3.3.7 483LM and 487LM antagonize Mcl-1 function 
 
To provide direct evidence that these novel inhibitors can selectively bind and antagonize 
Mcl-1 function, we have employed a cell-free functional assay using purified mitochondria, 
recombinant Mcl-1 and Bcl-xL proteins, and the BIM BH3 activator peptide which binds to both 
proteins with high affinity. At 10 nM, the BIM BH3 activator peptide induces substantial release 
of Smac protein from mitochondria, and 30 nM of Mcl-1 and Bcl-xL completely inhibit this release 
(Figure 3.4b). 483LM and 487LM antagonize Mcl-1 and restore BIM-induced release of Smac 
protein from mitochondria starting at 1 μM. Consistent with their selective binding profile, in the 
Bcl-xL functional assay both Mcl-1 inhibitors fail to release Smac at the highest tested 
concentration of 9 μM (Appendix Figure 3.8). In contrast, as was expected, Bad BH3 sensitizer 
peptide binds and antagonizes Bcl-xL mitochondrial function. These data demonstrate that the 
483LM and 487LM function as potent and selective antagonists of Mcl-1 protein. 
 
3.3.8 483LM has on-target cellular activity  
 
Wild-type (WT), Bax knockout (Bax-/-), Bak knockout (Bak-/-), Bax/Bak double knockout 
(DKO), and Mcl-1 knockout (Mcl-/-) MEFs have been employed as models to establish the 
mechanism-based apoptosis and on-target activity.[22] At 10 μM, 483LM primarily causes cell 
death in WT and did not show cytotoxicity against DKO and Mcl-1-/- MEFs. There was also no 
effect on Bax-/- and Bak-/- knockout cell lines, indicating that both Bax and Bak contribute in 
mediating apoptosis induction by the compound.[23] As was expected, ABT-263, pan inhibitor of 
Bcl-2, Bcl-xL and Bcl-2 proteins, induced cell death in MEFs wild-type but not in DKO, Bax-/- or 
Bak-/- MEFs. However, Mcl-1-/- MEFs were even more sensitive to ABT-263 compared to WT 
cells, confirming the findings that Mcl-1 is a resistant factor to ABT-263 cell activity (Figure 3.4c 
).[24] These results demonstrate that 483LM has on-target activity and does not kill MEFs 
indiscriminately through non-apoptotic mechanisms. The specificity of this class of Mcl-1 
inhibitors was further confirmed by using mouse Eμ-myc lymphoma cells overexpressing an 
72 
 
individual pro-survival protein required for cell survival.[25] 483LM induced substantial cell 
death to Eμ-myc lymphoma cells overexpressing Mcl-1 with minimal effect on cells 
overexpressing Bcl-2 or Bcl-xL (Figure 3.4d), which are sensitive to ABT-263 (Appendix Figure 
3.9a). As expected, the inactive analog 486LM did not affect the cells overexpressing Mcl-1 
(Appendix Figure 3.9b).  These data demonstrate that 483LM specifically kills cells that are 
dependent on Mcl-1 for survival, including tumor cells “addicted” to Mcl-1. 
 
 
Figure 3.4.Developed inhibitors exhibits on-target activity towards Mcl-1 in in vitro and cell-
based assays. (A) Pulldown assay showing the ability of 382LM, 483LM, and 491LM to disrupt 
Mcl-1/Noxa interaction but not the inactive compound 486LM. (B) 483LM and 487LM can inhibit 
the function of Mcl-1 in the mitochondria functional assay. (C) 483LM induces Bax/Bak 
dependent cell death in model MEFs. (D) Eµ-myc lymphoma model cells overexpressing and 
dependent on Mcl-1 for survival show the highest sensitivity to 483LM compared to Eµ-myc 
lymphoma cells overexpressing Bcl-2 or Bcl-xL 
 
3.4 Materials and methods 
 
Molecular docking calculations  
Molecular docking calculations were performed using the GOLD molecular docking tool.1 To 
begin with, the docking software tool GOLD was validated.2 For this purpose, the initially reported 
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bound conformation of ligand in the Mcl-1 active site (PDB: 4HW2) was extracted from its active 
site and subsequently docked using the GOLD molecular docking package. The binding site was 
defined as a 10 Å cavity around the corresponding ligand in the Mcl-1 binding site. Hydrogen 
atoms were added to the Mcl-1 protein using GOLD, with default settings of the amino acid 
protonation pattern. Side chains of amino acids were treated as rigid entities. Compounds were 
docked 10 times into the defined binding site by applying the following parameters of the GOLD 
genetic algorithm (GA) (population size = 100, selection pressure = 1.1, no. of operations = 
100000, no. of islands = 5, niche size = 2, migrate = 10, mutate = 95, crossover = 95) and different 
scoring functions available in GOLD. The best agreement between the crystallized and docked 
pose was obtained using ChemPLP scoring function These settings were also used in the molecular 
docking calculations of the selected compounds from our synthesized series.[26, 27] 
Protein purification 
His-tagged proteins containing Human Mcl-1 (residues 171–323), the isoform 2 construct of the 
human Bcl-2 [Bcl2-2 construct for protein production starts with the Bcl2 sequence of 1-34 aa, 
followed by the Bcl-xL sequence of 35-50 aa, and ends with the Bcl2 sequence of 92-202aa.], and 
Bcl-xL (Human Bcl-xL protein, which has an internal deletion for the 45-85 amino acid residues 
and a C-terminal truncation for the amino acid residues 212-233) were expressed from the pHis-
TEV vector (a modified pET vector) in E. coli BL21 (DE3) cells. Cells were grown at 37 ºC in 
2×YT, containing antibiotics to an OD600 density of 1.5, 1, and 0.8 for Mcl-1, Bcl-xL, and Bcl-2, 
respectively. Protein expression was induced by 0.4 mM IPTG at 20 ºC overnight. Cells were lysed 
in 20 mM HEPES pH 7.5, 200 mM NaCl, 0.1% βME and 40 µL of Leupeptin/Aprotinin (Mcl-1), 
25mM Tris pH 8.5, 200mM NaCl (Bcl-2), and 50mM Tris pH 7.5, 200 mM NaCl (Bcl-xL). All 
proteins were purified from the soluble fraction using Ni-NTA resin (QIAGEN), following the 
manufacturer’s instructions. For purification of TEV-cleaved protein, the amino terminal His tag 
was cleaved by incubation with TEV protease and the protein was further purified by anion 
exchange (Source Q) and gel filtration chromatography (Superdex 75, Amersham Biosciences) in 
20mM HEPES pH 7.0, 50 mM NaCl (Mcl-1), 25 mM Tris pH 8.5, 150 mM NaCl, 0.1% βME (Bcl-
2) and 20 mM Tris pH 7.5, 150 mM NaCl, 0.1% βME (Bcl-xL). His-tagged Mcl-1 protein was 
used for TR-FRET assay and HSQC-NMR. His-TEV cleaved Mcl-1, Bcl-2 and Bcl-xL were used 
in fluorescent polarization and surface plasmon resonance binding assays. 
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Crystallization and structure determination of Mcl-1 bound to inhibitors 
Prior to crystallization, for the Mcl-1:396 complex, Mcl-1 protein (residues 171-320) was 
concentrated to 10.66 mg/mL in 20 mM HEPES pH 7.0, 50 mM NaCl and incubated in a 1:1.5 
molar ratio with compound 396 at 4 °C for 48 hours.  The final DMSO concentration in the protein-
ligand sample was 6%. The complex crystallized in a sitting drop vapor diffusion experiment 
against well solution of 30% PEG 3350, 0.2 mM MgCl2 and 0.1 M ADA pH 6.5. The drops 
consisted of 1.5 µL protein-complex, 0.3 µL of 30% 6-aminohexanoic acid, and 1.2 µL of well 
solution.  Crystals grew within 1 day at 20 °C and were cryoprotected in 30% PEG 3350 prior to 
data collection.  
To crystallize Mcl-1:382LM and Mcl-1:462LM complexes, protein was concentrated to 10 
mg/mL and incubated with compound 1:1.5 ratio for 24 hours at 4 °C. Mcl-1:382LM and Mcl-
1:462LM grew crystals from drops containing equal volumes of protein and well solution setup 
against 23 % PEG 3350, 0.1 M Tris pH 8.0 and 18% PEG 3350, 200 mM NH4 Acetate, 100 mM 
Bis-Tris pH 6.5, respectively. The crystals were cryoprotected in a well solution containing 25% 
ethylene glycol.  
Diffraction data were collected on LS-CAT 21-ID-D (396LM) and 21-ID-G (382 LM and 
462LM) beamlines at the Advanced Photon Source at Argonne National Laboratory and processed 
with HKL2000.[28] The structures were solved via molecular replacement in Molrep [29] using 
an in-house Mcl-1:Bim structure missing helix 237-257 as the search model. Iterative rounds of 
electron density fitting and refinement were completed using Coot [16] and Buster [30], 
respectively. The coordinates and geometric restraints for each inhibitor were created from smiles 
using Grade with the qm+mogul option.[30] The coordinates were validated with Molprobity.[31] 
Data collection and refinement statistics are listed in (Appendix Table 3.5). Difference electron 
density maps showed one inhibitor bound in the BH3 binding pocket of each protein chain. In the 
case of 396LM and 382LM, several additional inhibitor compounds act as additives enabling 
crystal packing. Residues 172-320 are present in protein chains A, B, and D of Mcl-1:462LM. 
Chain C contains residues 171-321 plus one N-terminal residue of the cleaved tag. In the Mcl-
1:382LM crystal, residues 171, 197-200, and 322-323 are missing from chain A; residues 171, 
193-201, and 322-323 are missing in chain B; residues 194–202, 238-240, and 321-323 are missing 
in chain C; and residues 171, 198-201, and 321-323 are missing from chain D. In the Mcl-
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1:396LM structure, residues 171 and 197-202 are missing from the single protein chain in the 
asymmetric unit. 
Fluorescence polarization-based binding assays 
 
Fluorescein tagged BID BH3 peptide was used as a tracer in the FP-based binding assays. Two 
fluorescent labeled BID BH3 peptides were used: i) fluorescein tagged Bid peptide (Flu-Bid), 
labeled with fluorescein on the N-terminus of the BH3 peptide (79-99); ii) Bid BH3 peptide (80-
99) labeled with 5-FAM, named as FAM-Bid (Abgent). The Kd values were determined using 2 
nM of Flu-BID with different concentrations of Mcl-1 protein, or FAM-Bid with different 
concentrations of Bcl-2 and Bcl-xL proteins in a final volume of 125 µL in the assay buffer (20 
mM potassium phosphate, pH 7.5; 50 mM NaCl, 1 mM EDTA, 0.05% Pluronic F68 and, 4% 
DMSO). Plates were mixed and incubated on a shaker at room temperature for 3 hours and the 
polarization values in millipolarization units (mP) were measured at an excitation wavelength of 
485 nm and an emission wavelength of 530 nm. Dissociation constants (Kd) were calculated by 
fitting the sigmoidal dose-dependent FP increases as a function of protein concentrations using 
Graphpad Prism 6.0 software. Based upon analysis of the dynamic ranges for the signals and their 
Kd values, Flu-BID was selected as the tracer in the Mcl-1 while FAM-Bid was selected as the 
tracer for the rest of the proteins, Bcl-2, A1/Bfl-1, Bcl-w, and Bcl-xL. In our saturation 
experiments, the Kd value of Flu-Bid to Mcl-1 was 3.04 ± 0.06 nM, and the Kd values of FAM-
Bid to Bcl-2 was 18.44 ± 1.40 nM, and to Bcl-xL was 20.04 ± 2.34 nM, respectively. Based on the 
Kd values, the concentrations of the proteins used in the competitive binding experiments were 10 
nM for Mcl-1, 60 nM Bcl-2, 80 nM Bcl-xL and 40 nM for Bcl-w. The fluorescent probes, Flu-Bid 
and FAM-Bid were fixed at 2 nM for all assays. 5 μL of the tested compound in DMSO and 120 
μL of protein/probe complex in the assay buffer (20 mM potassium phosphate, pH 7.5; 50 mM 
NaCl, 1 mM EDTA and 0.05% Pluronic F68) were added to assay plates (Corning #3792), 
incubated at room temperature for 3 h and the polarization values (mP) were measured at an 
excitation wavelength at 485 nm and an emission wavelength at 530 nm using the plate reader 
Synergy H1 Hybrid, BioTek. IC50 values were determined by nonlinear regression fitting of the 





Competitive surface plasmon resonance based assay using immobilized Bim BH3 peptide 
The solution competitive SPR-based assay was performed on Biacore 2000. Bim BH3 peptide 
(141–166 amino acids) was immobilized on a streptavidin (CM5) chip with density of 770 RU 
(Response Units). The preincubated Mcl-1 protein (10 nM) with tested small-molecule inhibitors 
for at least 30 min (in 20 mM potassium phosphate, pH 7.5; 50 mM NaCl, 1 mM EDTA, 0.05% 
Pluronic F68 and, 4% DMSO) was injected over the surfaces of the chip in 1x PBS-P buffer (GE 
healthcare, #28-9950-84). Response units were measured after 15 s from the end of a two-minute 
association phase, and the specific binding was calculated by subtracting the control surface (Fc1) 
signal from the surfaces with immobilized biotin-labeled Bim BH3. IC50 values were determined 
by nonlinear least-squares analysis using GraphPad Prism 6.0 software. 
Cell culture and cell viability assays 
MEFs, wild type, Bax knock out, Bak knock out and Bax/Bak double knock out, were gifts from 
Dr. Shaomeng Wang at the University of Michigan and were cultured in DMEM (Life 
Technologies), supplemented with 10% fetal bovine serum (FBS) (Thermo Scientific HyClone), 
and 1% Penicillin/streptomycin solution (Life Technologies). The retroviral transduced lymphoma 
cells isolated from Eμ-myc transgenic mice were gifts from Ricky W. Johnstone at University of 
Melbourne, Melbourne, Australia and cultured as previously described.[25] PANC-1 was obtained 
from the American Type Culture Collection (ATCC). The cells were cultured in DMEM (Life 
Technologies), supplemented with 10% FBS and 1% Penicillin/streptomycin solution. MEFs were 
seeded in 24-well plates at 0.5 x 105 cells/well, left to adhere for 5 h and then treated for 15 h with 
increasing concentrations of the compounds. The cells were harvested, washed with phosphate-
buffered saline (PBS), and stained with 0.025 mg/ml propidium iodide (MP Biomedicals). The 
percentage of propidium iodide positive population was determined by flow cytometry and 
calculated using WinList 3.0. The Mcl-1, Bcl-2 and Bcl-xL retroviral transduced lymphoma Eμ-
myc cells were seeded in 12-well plates at 0.5 x 106 cells/well. They were treated with different 
concentrations of tested compounds for 16 h. The cells were harvested and stained with violet 
LIVE/DEAD Fixable Dead Cell Stain Kit (Invitrogen), according to manufacturer's protocol.  The 
percentage of fluorescent positive cells was determined by flow cytometry and calculated using 
WinList 3.0. In 96-well plates, the effect of the compounds on tested PANC-1 cells viability was 
evaluated after 48 h by MTT Cell Proliferation Assay (Amresco) where MTT solution (12 mM) 
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was added to the cultures (10 µL MTT solution per 100 µL medium) and incubated for 4 h. Sodium 
dodecyl sulfate (Fisher) solution (1 g/10 ml) was added to the cultures (100 µL per well), which 
was incubated overnight. The absorbance was detected at 570 nM using the plate reader Synergy 
H1 Hybrid, BioTek. IC50 values were calculated by non-linear regression analysis using GraphPad 
Prism 6.0 Software. 
 
Pulldown assay 
2LMP, a subclone of MDA-MB-231, was kindly provided by Dr. Shaomeng Wang at the 
University of Michigan. The cells were harvested (~15x106) and lysed via sonication with CHAPS 
buffer (10 mM HEPES (pH 7.4), 2.5 mM EDTA, 150 mM NaCl, 1% (w/v) CHAPS). Pre-cleared 
cell lysates (1 mg/mL) were treated with varying concentrations of compounds and then subject to 
overnight incubation at 4° C with biotinylated Noxa peptide (18–43). Protein-peptide complexes 
were pulled down with streptavidin-agarose beads for 2 h. Beads were washed with CHAPS buffer 
and Mcl-1 protein was eluted by boiling in SDS-PAGE buffer. Samples were analyzed by western 
blotting with the Mcl-1 antibody (Thermo Scientific #MS-681-P1). 
 
Mitochondria-based functional assay 
2LMP cells were cultured in DMEM (Life Technologies), supplemented with 10% FBS and 1% 
Penicillin/streptomycin solution. Cells were cultured in 150 cm2 cell culture dishes up to 80% 
confluent in a healthy state. The cells were harvested and washed two times with cold PBS. 
Cell pellets were suspended in the mitochondrial isolation buffer (MIB, 10 mM Tris Hcl, 0.1 mM 
EDTA, 250 mM sucrose with protease inhibitors and 1 mM PMSF added immediately prior to the 
assay, pH 7.4). The cells were incubated at 4oC for 20 min. The cells are homogenized on ice using 
40 strokes using 2 ml Dounce glass homogenizer and pestle B. Mitochondria were then isolated 
by differential centrifugation steps followed by two washes with MIB. Mitochondria is then 
suspended in mitochondrial reaction buffer (MRB, 20 mM HEPES, 100 mM KCl, 2.5 mM MgCl2, 
100 mM sucrose with 1mM DTT and protease inhibitors and 1 mM PMSF added immediately 
prior to the assay, pH 7.5). 
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The concentration of mitochondria suspension was adjusted to 50 µg per aliquot.  The aliquots 
were incubated with 30 nM of Mcl-1, Bcl-2, or Bcl-xL protein, together with BIM (141-166) 
peptide, and Noxa (20-45), Bad (102-128) or different concentrations of 483LM, at 37oC for 1 h. 
Mitochondria treated with DMSO were included as the negative control. Cytochrome c and Smac 
released to the supernatant and remaining in the mitochondria pellets were analyzed by western 
blotting using primary anti-cytochrome c and anti-Smac antibodies from Cell Signaling and 




Ahmed Mady performed FP and SPR binding assays, analyzed the SAR results and participated 
in the discussion of designing novel analogs. He also established and optimized the functional 
assay and performed all cell-based assays. Dr. Lei Miao synthesized all compounds. The 
computational docking studies of novel designed analogs based on the SAR studies were done by 
Dr. Andrej Perdih, visiting scholar in Dr. Nikolovska-Coleska’s laboratory from the National 
Institute of Chemistry in Ljubljana, Slovenia. Karson Kump performed the pulldown assay. 
Expression and purification of all proteins as well as crystallographic studies were performed in 
Dr. Jeanne Stuckey’s lab at LSI. TR-FRET binding assay was performed by Dr. Yuhong Du in Dr. 













Figure 3.5.Omit electron density maps for the bound ligands of Mcl-1.The structures of Mcl-
1 absent the ligands were refined in Buster [30] and their subsequent difference (Fo-Fc) electron 
density maps are shown as green grids contoured at 3 sigma. The positions of the refined ligands 
are shown as sticks with nitrogens (blue), sulfurs (yellow), oxygens (red) and carbon atoms for 




Figure 3.6.Binding affinity of 483LM, 487LM and Noxa using competitive SPR-based 
assay. 
 
Figure 3.7.Selectivity profile of 483LM and 480LM using Competitive FP-based assay. 
483LM shows a notable decrease in binding to Bcl-2 compared 480LM indicating the importance 
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Figure 3.8.Mitochondrial functional assay showing the inability of 483LM to inhibit the 
function of Bcl-xL like Bad peptide. This confirms the selectivity data generated in biochemical 
assays. 
 
Figure 3.9.Using Eµ-myc lymphoma cell lines to confirm the selectivity of ABT-263 and 
inactivity of 486LM. (A) ABT263induces cell death in Eµ-myc lymphoma cells overexpressing 
Bcl-2 or Bcl-xL but not Mcl-1. (B) The inactive compound 486LM dos not affect Eµ-myc/Mcl-1 
cells. 
 
Table 3.5.Crystallography data collection and refinement statistics. 
Data Collection Mcl-1:396LM Mcl-1:382LM Mcl-1:462LM 
PDB ID XXXX XXXX XXXX 
Space Group R32 P212121 P212121 






Wavelength (Å) 0.96295 0.97856 0.97856 
Resolution (Å)1 2.55 (2.55-2.59) 2.74 (2.74-2.79) 2.10 (2.10-2.14) 
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Rmerge2 0.069 (0.649) 0.095 (0.355) 0.064 (0.464) 
<I/ I>3 20 (5) 10 (3) 10 (3) 
Completeness (%)4 99.6 (100) 99.3 (97.6) 100 (100) 
Redundancy 20.5 (21.5) 5.3 (4.9) 7.4 (7.5) 
 
Refinement 
   
Resolution (Å) 2.55 2.75 2.1 
R-Factor5 0.212 0.2297 0.1874 
Rfree6 0.251 0.2616 0.2215 
Protein atoms 1081 4256 4725 
Water Molecules 10 24 188 
Unique Reflections 5816 14204 39167 
R.m.s.d.7    
   Bonds (Å) 0.010 0.008 0.01 
   Angles (°) 1.04 0.90 0.90 
Molecules/ASU 1 4 4 
MolProbity Score 2.38 1.54 0.94 
Clash Score 4.52 2.39 1.76 
Z-Score8    
RSCC (%)8    
RSRV (%)8    
1Statistics for highest resolution bin of reflections in parentheses.  
2Rmerge =hj | Ihj-<Ih> | /hjIhj, where Ihj  is the intensity of observation j of reflection h and <Ih> is the mean intensity for multiply recorded 
reflections. 
3Intensity signal-to-noise ratio. 
4Completeness of the unique diffraction data. 
5R-factor = h |IFo| – |Fc| | / h|Fo|, where Fo and Fc are the observed and calculated structure factor amplitudes for reflection h. 
6Rfree is calculated against a 5% random sampling of the reflections that were removed before structure refinement. 
7Root mean square deviation of bond lengths and bond angles. 
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CHAPTER 4  




Taking individual differences into account while exploring prevention and treatment 
strategies for diseases is not a new idea. This concept of precision medicine has been used for a 
long time in tackling individual patient variabilities. An example is determining the blood type of 
patients before blood transfusion. This concept is under continuous improvement due to advances 
in understanding diseases and characterizing of patients through various assays and tests in 
addition to genomics, proteomics, and metabolomics. [1] 
 
4.1.1 Promise and limitations of genetic markers for patient stratification 
 
Although there are assays that can predict the sensitivity or resistance of some types of 
cancer, there are still unanswered questions and a lot to explore in the realm of precision oncology. 
There are numerous challenges that need to be addressed such as understanding drug resistance, 
the use of optimized drug combinations, the heterogeneity of tumor genomics, as well as the ability 
to closely monitor tumor response and recurrence. One of the methods to determine the sensitivity 
of tumors to certain therapeutics is the use of functional assays. The idea is to monitor the states 
of a live tumor and help in guiding individualized therapy, for example determining tumor death 
when treated with certain drugs ex vivo.[2] There is recent progress in the area of functional assays 
that guide clinicians in gaining predictive information about tumors under investigation. These 




An example of novel functional assays is 3D organoid drug toxicity where cancer cells 
from patients are grown into a semi-solid extracellular matrix using media enriched with growth 
factor.[3] Another example is 3D culture cytotoxicity where tumor cells are grown in a multi-cell-
type 3D model to preserve the gene expression patterns similar to the tumor microenvironment. 
This type of culture shows significant differences in drug sensitivity when compared with cancer 
cells grown in a monolayer or in 3D organoid culture.[4] There are also patient-derived xenograft 
(PDX) mouse models that are used in order to closely mimic the tumor microenvironment where 
patient-derived tumors are implanted subcutaneously or orthotopically. These models are not only 
used for drug discovery to test efficacy, but they could be used as a method for determining the 
most accurate patient therapies.[5] Another functional assay that has been used in the last years is 
Bcl-2 homology domain 3 (BH3) profiling which is the focus of this chapter. 
 
4.1.2 BH3 profiling assay 
 
BH3 profiling is a method to determine how a certain tumor evades apoptosis.[6] The 
advantage of this method is the ability to quickly detect expected drug responses within a few 
hours without the need for tedious cell culture. BH3 profiling is used in identifying the dependence 
on anti-apoptotic proteins, which is more accurate than determining the expression of these 
proteins on the transcriptional or translational level.[7, 8]  
 
Mitochondria regulate apoptosis 
As stated previously, the Bcl-2 family of proteins is a key regulator of the intrinsic 
apoptotic pathway. This is controlled by the interaction between anti-apoptotic and pro-apoptotic 
proteins.[9] The pro-apoptotic proteins are divided into activators, sensitizers, and effectors. Once 
effectors (e.g. Bax and Bak) are activated, their monomer form is converted to oligomers that form 
pores in the mitochondrial outer membrane, leading to membrane permeabilization, leading to the 
release of cytochrome c to the cytoplasm.[10] The activators are pro-apoptotic BH3-only proteins 
(e.g. Bim and Bid), which can directly induce the activation of effectors.[11] The sensitizer BH3-
only pro-apoptotic proteins (e.g. Noxa, Bad, Hrk, Bik, Bmf and Puma) cannot directly induce the 
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activation of effectors, but they displace activators from binding to the anti-apoptotic proteins so 
they are considered the inhibitors of apoptosis inhibitors (Figure 4.1).[12] 
 
Figure 4.1.Bcl-2 family regulation of apoptosis. Cellular stress leads to the activation of BIM 
and BID leading to the activation of effectors and ultimately cell death. 
 
BH3 profiling detects three classes of apoptotic evasion 
In BH3 profiling, the mitochondria are exposed to a series of synthetic BH3 domain 
containing peptides that have different selectivity profiles towards anti-apoptotic proteins and 
detecting mitochondrial outer membrane permeabilization (MOMP). By pinpointing the pattern 
by which BH3 peptides induce MOMP, the method by which the cancer evades apoptosis can be 
determined.  
There are majorly three distinct apoptosis evasion mechanisms that cancer cells use to 
evade the intrinsic apoptotic pathway (Figure 4.2). First, the elimination or reduction of effector 
proteins activation, which could be due to deletion of crucial pro-apoptotic BH3-only genes (class 
A), like in large cell lymphoma SU-DHL-8. Second, the elimination or reduction of the effector 
proteins, Bax and Bak, leading to a profound blockage of the apoptotic pathway due to the fact 
that Bax and Bak are crucial for the execution of pro-apoptotic function (class B). This can be 
detected in large cell lymphoma SU-DHL-10.[13] Finally, activation of Bax and Bak might be 
evaded through the expression of anti-apoptotic proteins like Bcl-2, Bcl-xL, and Mcl-1 (class C). 
The cells that adopt the class C evasion pathway are considered primed for death and can be 




Figure 4.2.BH3 profiling distinguishes between three classes of apoptosis evasion. 
 
Class C cell lines are the focus of the studies since they can be a promising target for Mcl-
1 inhibitors, if they are Mcl-1 dependent. Based on the selectivity profile of the synthetic peptides 
used (Figure 4.3), the anti-apoptotic protein that is crucial for survival can be identified. If Noxa 
triggers a high mitochondrial depolarization but significantly less using Bad, then the tumor is 
most likely to be dependent on Mcl-1 for survival while the opposite will indicate dependence on 
Bcl-2 and/or Bcl-xL. MS1 is a synthetic peptide that was developed to be used in BH3 profiling 
due to its superior potency to Mcl-1 compared to Noxa.[14] Using MS1 is a better alternative to 
be used since its binding affinity to Mcl-1 is similar to the binding affinity of Bad to Bcl-2, Bcl-




Figure 4.3.Selectivity profile of synthetic BH3 peptides and small-molecule BH3 mimetics. 
 
Mitochondrial outer membrane permeabilization 
 Originally, BH3 profiling was performed by isolating mitochondria from cells and treating 
with various synthetic BH3 peptides derived from BH3-only domain proteins. The induction of 
MOMP was measured with western blotting or ELISA to detect cytochrome c release.[12, 15] This 
method required tens to hundreds of millions of cells to isolate enough mitochondria for various 
peptide treatments. A new technique for BH3 profiling was later developed to take advantage of 
the correlation between MOMP and change of the fluorescence of JC-1 (5,5’,6,6’-tetrachloro-
1,1’,3,3’- tetraethylbenzimi-dazolylcarbocyanine iodide) from red to green. JC-1 is a lipophilic 
cation existing in a monomeric form and emits in the green region. It is widely used for 
microscopic and cytometric determination of mitochondrial membrane potential. In healthy 
mitochondria possessing high membrane potential, it accumulates in the mitochondria and forms 
J-aggregates and reversibly changes in fluorescence emission from green to red/orange. In cells 
with depolarized mitochondria (low mitochondrial membrane potential), JC-1 remains in 
cytoplasm as J-monomers, emitting green fluorescence. [16]  
 The use of JC-1 allowed the use of plate-based whole cells for BH3 profiling. Digitonin is 
used to permeabilize the cell membrane and allow introduction of synthetic peptides into the cells. 
The digitonin efficiency is directly proportional to membrane cholesterol, which is higher in the 
cell membrane compared to the mitochondrial membrane, so the concentration is only sufficient 
to permeabilize the cell membrane without harming the mitochondrial membrane.[17] A trehalose-
based buffer is used in order to stabilize the mitochondria in permeabilized cells.[18] The 
advantage of this technique is that a few thousand cells are needed for the experiment and MOMP 




Figure 4.4.Whole cell BH3 profiling. The cells are suspended in trehalose based buffer and then 
transferred into wells containing JC-1, digitonin, and peptides. The JC-1 red fluorescence is 
measured in 5 minutes’ intervals for 90 to 180 minutes. For ease of comparison, the kinetics data 
can be normalized and presented by selecting a fixed point at 90, 120, or 180 minutes, or 
calculating the area under the curve. 
  
 BH3 profiling can also be determined using flow cytometry. The advantage of flow 
cytometry is the ability to test specific cell populations in heterogeneous samples, especially if it 
is difficult to enrich the cell population to be used in the plate-based assay. In this method TMRE 
is usually the best choice.[19] 
 A new concept that is introduced lately is Dynamic BH3 profiling (DBP). This method 
measures the changes in priming induced through treatment with compounds prior to BH3 
profiling. So if one tumor is resistant to a certain drug and another tumor is sensitive, the sensitive 
one will show more priming after treatment with sub-lethal dose of the drug while the resistant 
tumor will have no change in BH3 profile. Implementing DBP can aid in determining the best 
treatment that can be used to treat a certain type of cancer in a very short time, even if it takes 
several days for the drug to induce cell death. This method can be used on primary cancer cells 
where there is no need to wait for one or more days to determine the most effective treatment.[20]  
 
4.1.3 Cancers that show dependence on the Bcl-2 family proteins for survival 
   
 In this study, the focus will be on four types of cancer: multiple myeloma and leukemia, as 
examples of hematologic tumors; as well as head and neck squamous cell carcinoma and pancreatic 
cancer, as examples of solid tumors.  
Multiple myeloma (MM) is a hematologic malignancy and accounts for approximately 
10% of all hematologic cancers.[21] Even though progress in the treatment of this disease has been 
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made, multiple myeloma remains largely incurable by current standard treatments and new 
therapeutic strategies are needed.[22] Recent advances in genomic and proteomic studies of MM 
have shown that the survival and resistance to chemotherapy of myeloma cells is dependent on 
defects in the programmed cell death pathway. Mcl-1 is highly upregulated in MM samples of 
patients at diagnosis, as well as in samples taken at relapse, and correlates with resistance to 
chemotherapy, relapse, and shorter survival times. [23-25] Downregulation of Mcl-1 significantly 
increased apoptosis in MM cell lines and plasma cells from MM patients [23].  
Acute myeloid leukemia (AML) is a malignancy in which the bone marrow is replaced by 
immature myeloid cells. 70% of patients diagnosed with AML die from this malignancy. Mcl-1 is 
important for the survival of AML cells. This is confirmed by experiments based on the 
implementation of genetic methods to downregulate the expression of Mcl-1, in order to test its 
effect on survival of AML cells. [26]  Knocking down the mcl-1 gene has led to the spontaneous 
apoptosis of AML cells.  
 Head and neck squamous cell carcinoma (HNSCC) is composed of a heterogeneous group 
of tumors in the upper aero digestive tract, and is the sixth most common cancer in the world.[27] 
The 5-year survival rate is poor, with only small improvement in the past few years despite 
improvements in surgical procedures, radiotherapy, and chemotherapy.[28] The majority of head 
and neck carcinomas are highly resistant to various chemotherapy and radiotherapy regimens, 
highlighting the clinical need for alternate modalities of treatment for these cancers.[29] One of 
the HNSCC hallmarks is overexpression of the anti-apoptotic proteins of the Bcl-2 family. [30] 
Thus, new approaches are needed to identify key tumor-specific survival pathways, targeted 
therapeutics, and biomarkers to predict drug sensitivity in this disease.  
Pancreatic cancer is among the most therapy resistant cancers, with a poor prognosis and 
high mortality rate. [31] The only possible curative treatment is surgical removal with five-year 
survival rate below 5%. [32] Although gemcitabine is the drug of choice in the treatment of 
pancreatic cancer, it produces a limited improvement in overall survival. [33] It has been shown 
that downregulation of Mcl-1 using siRNA approach enhances the induction of apoptosis and 
sensitivity of pancreatic cancer to gemcitabine and radiation, providing evidence that Mcl-1 might 
play an important role in pancreatic cancer biology.[34, 35]  
92 
 
Thus, Mcl-1 represents an attractive molecular target for designing a new class of agents 
for treatment of these types of cancer and overcoming resistance to chemotherapeutics. It is clear 
now that Mcl-1 is a validated target that can aid in the ongoing war against cancer. 
 Since BH3 profiling is important in determining the dependence on different anti-apoptotic 
proteins, this method is implemented in screening hematologic and solid tumors to determine the 
most sensitive cell lines to our novel and selective Mcl-1 inhibitors. This was further confirmed 
by the ability of Mcl-1 inhibitors to induce the hallmarks of apoptosis in cancer cell lines that 
depend on Mcl-1 for survival. 
 
4.2 Results 
4.2.1 BH3 profiling determines anti-apoptotic survival dependence 
 
 In this study, six established MM cell lines (H929, OPM-2, KMS-11, MM.1S, RPMI 8226 
and U266) and three leukemia cell lines (ML2, THP-1 and K562) were obtained as representatives 
for hematologic tumors. For solid tumors, three pancreatic cell lines (PANC-1, MIA PaCa-2 and 
BxPC-3) and 12 HNSCC cell lines (UM47, UM97, UM23, UM59, UM104, UM110, UM69, 
UM14a, UM92, UM58, 93-VU-147 and UM49) were generously provided by Dr. Thomas Carey. 
BH3 profiling was performed to determine the anti-apoptotic proteins upon which these cell lines 
are dependent.  
In MM cell lines three cell lines (H929, OPM2, and KMS-11) showed dependence on Mcl-
1 for survival (Figure 4.5a). Although KMS-11 does not show Mcl-1 dependence at 8 µM like 
OPM2, increasing peptide concentration to 16 and 32 µM clearly showed a significantly increasing 
percentage of MOMP by MS1, the selective Mcl-1 peptide, indicating the dependence on Mcl-1 
for survival. Bad but not MS1 induced around 60-80% mitochondrial depolarization when testing 
MM.1S, RPMI 8226, and U266, indicating the dependence on Bcl-2/Bcl-xL but not Mcl-1. The 
results for H929, OPM2, MM.1S, and RPMI 8226 were consistent with reported data regarding 




Figure 4.5.BH3 profiling distinguishes between Mcl-1 and Bcl-2/Bcl-xL dependence. BH3 
profiling performed in (A) Multiple myeloma (B) Leukemia (C) Pancreatic cancer and (D) Head 
and neck cancer. 
 
 Tested leukemia cell lines, ML2 and THP1, showed Mcl-1 and Bcl-2/Bcl-xL co-
dependence. However, THP1 showed a lower percentage of mitochondrial depolarization by Bad 
and MS1 compared to ML2 at the same peptide concentrations used (10 µM).  K562 showed no 
dependence on Mcl-1, confirmed by the diminished mitochondrial depolarization up to 100 µM of 
MS1 (Figure 4.5b).  
Interestingly, the three tested pancreatic cell lines showed co-dependence on Mcl-1 and 
Bcl-2/Bcl-xL (Figure 4.5c), which is consistent with data generated previously in our lab using 
siRNA studies as well as other labs. [34, 39]  
Based on the BH3 profiling results, the HNSCC cells lines can be categorized into three 
groups: Mcl-1 and Bcl-2/Bcl-xL co-dependent (UM47, UM97, UM23, UM59, and UM104), Bcl-
2/Bcl-xL dependent (UM110, UM69, UM14a, UM92, UM58, and 93-VU-147) and Mcl-1 
dependent (UM-49) (Figure 4.5d). These results correlate with reported data indicating that Bcl-
xL and less frequently Bcl-2 are major players in conferring resistance in HNSCC cell lines. [40-
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42] The co-dependence of HNSCC cells on Bcl-2, Bcl-xL, and Mcl-1 was also confirmed in 
literature by treating the cells with ABT-737 and showing that this treatment was not enough in 
inducing cell death, but in combination with Noxa siRNA the cell death was promoted. [43] 
To gain better understanding about the survival dependence of the cancer cell lines and 
predict their sensitivity, it is important to analyze the correlation between BH3 profiling data and 
the expression of anti-apoptotic genes. For this purpose, the Mcl-1, Bcl-2, and Bcl-xL gene 
expression data reported for the tested cell lines were obtained from Expression Atlas public 
repository (Table 4.1). [44] 
 
Table 4.1.RPKM expression levels of anti-apoptotic proteins based on RNA-Seq data. RPKM 
in (A) Multiple myeloma (B) Leukemia and (C) Pancreatic cancer.[44] 
 
 Using the expression data, the percentage of mitochondrial depolarization by 8 µM MS1 
peptide was plotted against the expression levels of anti-apoptotic proteins in MM cell lines. The 
data indicated that there was no correlation (R2 = 0.37) between the percentage of mitochondrial 
depolarization and Mcl-1 expression (Figure 4.6a). However, there was an inverse correlation with 
Bcl-xL expression (R2 = 0.63), which is consistent with expected mitochondrial depolarization. 
Higher expression of Bcl-xL will lead to less effect on the mitochondrial potential by MS1 peptide 
since it does not bind Bcl-xL protein (Figure 4.6b). With a Mcl-1/Bcl-xL expression ratio, a high 
positive correlation (R2 = 0.83) has been confirmed, indicating the importance of Mcl-1 gene 




Figure 4.6.Plots between percentage of mitochondrial depolarization by MS1 in multiple 
myeloma cell lines and RPKM expression levels. The plot of (A) Mcl-1; (B) Bcl-xL; and ratio 
of expression levels (C) Mcl-1/Bcl-xL and (D) Mcl-1/Bcl-2. 
 We then determined the in vitro sensitivity of multiple myeloma cell lines to the Mcl-1 
BH3 mimetic inhibitor, 483LM through MTT cell proliferation assay. As expected based on the 
BH3 profiling, data cell lines which were identified to depend on Mcl-1 for survival were more 
sensitive to 483LM. Plotting the IC50 values of growth inhibition versus percentage of 
mitochondrial depolarization by MS1 showed high correlation (R2=0.75) (Figure 4.7).     
 
Figure 4.7.The sensitivity of MM cell lines correlates with percentage of mitochondrial 
depolarization by MS1. 
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4.2.2 Pharmacological approach for confirmation of cancer cell survival dependence 
 
 To further confirm the data obtained by BH3 profiling and cancer cell survival dependence, 
small-molecule BH3 mimetics with different binding selectivity were used as pharmacological 
tools. Selective Mcl-1 inhibitor 483LM should mimic and behave in a similar manner as Noxa 
(and MS1), while ABT-263 is Bcl-2, Bcl-xL and Bcl-w inhibitor, as Bad BH3 mimetic. In addition, 
these studies will further confirm if these compounds act in an on-target mechanism.   
 Using the Mcl-1 dependent H929, 483LM was able to induce dose dependent mitochondrial 
depolarization, similar to Noxa, while ABT-263 did not trigger the depolarization, similar to Bad. 
In contrast, 483LM and Noxa did not show effect on the mitochondrial depolarization in the Bcl-
2/Bcl-xL dependent MM.1S cell line, while ABT-263 and BAD induce almost 100% 
depolarization of the mitochondrial potential at tested concentrations (Figure 4.8).  
 
Figure 4.8.BH3 profiling using 483LM and ABT263 resembles the selectivity of NOXA and 
BAD respectively. (A) BH3 profiling of Mcl-1 dependent H929 (B) BH3 profiling of Bcl-2/Bcl-
xL dependent MM.1S 
  
 This consistent data with the functional BH3 profiling assay were further confirmed with 
analyzing apoptosis induction in Mcl-1 dependent, H929, and non-dependent cells, MM.1S and 
U266. 483LM induced apoptosis in H929 after a treatment of 4 h, while it has almost no effect on 
MM.1S and U266 after 24 h of treatment (Figure 4.9). In contrast, ABT-263 induced apoptosis 




Figure 4.9.Detection of apoptosis induction after treatment with 483LM and ABT-263. 
Experiments are conducted in (A) MM.1S, (B) U266 and (C) H929 cell lines. 
 
 The same pattern was seen when HNSCC UM49 and UM110 were treated with 483LM, 
487LM, ABT-199 (selective Bcl-2 inhibitor) and ABT-263. 483LM induced dose-dependent 
apoptosis in UM-49 but not in UM-110 (Figure 4.10a).  
 
Figure 4.10.BH3 mimetics induce apoptosis in HNSCC UM-49 and UM-110 cell lines in 24 
hours consistent with the predicted survival dependence on the anti-apoptotic proteins. (A) 
Mcl-1 inhibitor; (B) Bcl-2 inhibitor; (C) Bcl-2/Bcl-xL inhibitor; (D) Mcl-1 inhibitor induces 
caspase-dependent apoptosis in sensitive UM-49 cell line. 
 As expected, ABT-199 and ABT-263 induced apoptosis in UM-110 more than UM-49 
(Figure 4.10b, c). It is worth nothing that ABT-263 is more potent in inducing apoptosis in UM110, 
in comparison to ABT-199, indicating that the survival of this cell line depends more on Bcl-xL 
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than on Bcl-2. Further studies to probe the mechanism of apoptosis induction showed that 487LM 
induces caspase-dependent apoptosis in UM-49 cells, which can be seen with the marked decrease 
in apoptosis when UM-49 cells were pretreated with the pan caspase inhibitors ZVAD (Figure 
4.10d).  
 Identified Mcl-1 survival dependence of UM-49 cells was further confirmed by 
implementing a genetic approach. Mcl-1 gene expression in UM-49 and UM-110 was successfully 
knocked down using Mcl-1 siRNA. UM-49 cell viability was profoundly affected while UM110 
was not significantly affected, further demonstrating that its survival does not depend on Mcl-1 
(Figure 4.11). 
 
Figure 4.11.Mcl-1 siRNA knockdown induces cell death to UM-49 but not to UM110. (A) 
Number of live cells counted using trypan blue and (B) Corresponding western blots. 
  
4.2.3 Selective Mcl-1 inhibitors activate the hallmarks of apoptosis in Mcl-1 dependent 
cancers 
 To confirm that these compounds act on-mechanism, we performed a series of assays 
designed to assess the sequential events that occur during activation of the intrinsic apoptosis 
pathway. For this purpose, H929 cell line was selected due to its Mcl-1 dependence. Using Co-
Immunoprecipitation, 483LM markedly disrupted the interaction between Mcl-1 and Bak, 
indicating the inhibition of Mcl-1 function as an anti-apoptotic protein (Figure 4.12a). Treating the 
cells with 483LM for 4 h was enough to show mitochondrial depolarization, which was detected 
by the conversion of JC-1 fluorescence from red to green (Figure 4.12b). Mitochondrial 
depolarization is usually correlated with the oligomerization of effector proteins (Bax or Bak), 
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followed by the release of cytochrome c and Smac. [45, 46] The release of Smac from 
mitochondria to cytosol was detected after 6 h of treatment with 483LM (Figure 4.12c).  
 
 
Figure 4.12.483LM disrupts the interaction between Mcl-1 and BAK inducing mitochondrial 
membrane depolarization and Smac release. (A) CoIP showing disruption of Mcl-1 and BAK 
interaction (B) Mitochondrial outer membrane depolarization detected using JC-1 (C) Cell 
fractionation assay indicating the release of Smac into the cytoplasm. 
 Smac release leads to the induction of cytochrome c-dependent caspase activation. [47] 
Caspase 3 activation was detected after 4 h of treatment with 483LM (Figure 4.13a). The activation 
of caspases mediates PARP cleavage, which is detected after treatment with 483LM (Figure 
4.13b). Overall the obtained results demonstrated that 483LM induces the hallmarks of apoptosis 
in the Mcl-1 dependent H929 cell line, including mitochondrial membrane depolarization, release 
of Smac, caspase-3 activation, and PARP cleavage. 
 
Figure 4.13.483LM induces caspase 3 activation and PARP cleavage. (A) Dose dependent 





4.2.4    In Vivo efficacy of 483LM in mouse xenograft models with Mcl-1 sensitive cell line 
 
 Based on the promising cellular activity of 483LM in H929 multiple myeloma cells and 
encouraged by the pharmacokinetic properties of 483LM (data not shown), we decided to test the 
in vivo activity of 483LM in the H929 xenograft tumor model. 483LM was administrated daily 
with IP injection at 30 and 60 mg/kg for 10 consecutive days. In this period 483LM did not cause 
any loss in the animal’s weight, and there was no obvious sign of toxicity during the course of the 
injections. The treatment with 483LM resulted in statistically significant (p < 0.001) dose-
dependent tumor growth inhibition in comparison with the control mice.  A 60 mg/kg dose 
completely suppressed the tumor growth, an effect which lasted 7 days after the end of the 
treatment (Figure 4.14). This experiment confirms the ability of 483LM to distribute to the tumor 
and reduce its growth in vivo.  
 
Figure 4.14.In vivo efficacy of 483LM in mouse xenograft model with Mcl-1 dependent H929. 
(*) p < 0.05(***) p < 0.001, Columns, mean; bars, SEM. ANOVA, Bonferroni's post-hoc test 
 
4.2.5 483LM causes cell death in Mcl-1 and Bcl-2/Bcl-xL codependent cell lines in 
combination with ABT 263. 
 
Mcl-1 has been well characterized as a resistance factor for the Bcl-2/Bcl-xL inhibitors and many 
reports have demonstrated that siRNA-mediated knockdown of Mcl-1 sensitizes cancer cells to 
death by Bcl-2/Bcl-xL inhibitors, such as ABT-737. Using BH3 profiling, we also showed that 
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pancreatic cancer cell lines are co-dependent on Mcl-1 and Bcl-2/Bcl-xL for survival. Thus, we 
tested the combination of ABT-263 and 483LM in PANC-1 and Mia PaCa2 cancer cell lines. As 
expected, ABT-263 had little effect on these cell lines (Figure 4.15). Combination treatment with 
483LM substantially shifted the dose–response curve of ABT-263 in both tested pancreatic cell 
lines, and IC50 of cell growth inhibition was improved more than 600-fold, indicating an ability to 
potentiate the effect of Bcl-1/Bcl-xL inhibition. These data further demonstrate that 483LM is 
indeed a cell-active Mcl-1 inhibitor that behaves as predicted in sensitizing cancer cells to the 
effects of Bcl-2/Bcl-xL inhibitors. 
 
Figure 4.15.483LM exhibits synergism with ABT263 in PANC-1 and Mia Paca2 cell lines 
that depends on Mcl-1 and Bcl-2/Bcl-xL for survival. (A) Cell growth inhibition of ABT263 




 BH3 profiling is a crucial tool in understanding the way cancer cells evade apoptosis. It 
can also be used to determine the sensitivity of cancer to cancer therapeutics as well as new drug 
candidates. It will be important to implement this method in clinical settings, to identify the types 
of cancer that can be effectively treated with Mcl-1 inhibitors that are introduced into the clinic, 
either as single agents or in combination with other therapeutics. Relying on levels of certain 
proteins or gene expressions might not be enough to identify the best candidate therapeutics to the 
type of tumor under investigation. In this study it was shown that Mcl-1 dependence, marked by a 
higher percentage of mitochondrial depolarization by Noxa or MS1 compared to Bad, might not 
necessarily correlate solely with the expression level of Mcl-1. Other anti-apoptotic gene 
expression levels could contribute to the overall Mcl-1 dependence. The implementation of BH3 
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profiling in a large panel of cell lines can help us understand the major players that add to the 
resistance or sensitivity of different types of cancer.  
 In this study, it was shown that Mcl-1 dependent cell lines showed the highest sensitivity 
to our developed inhibitors, while the Bcl-2/Bcl-xL dependent cell lines were the most resistant as 
determined by MTT cell viability assays. 483LM disrupted the interaction between Mcl-1 and Bak 
and induced apoptosis in 4 h as shown by annexin-V staining. Other hallmarks were activated, 
including Smac release from the mitochondria into the cytosol, activation of caspase 3, and PARP 
cleavage. Although cell lines such as PANC-1 and BxPC3 that are codependent on Mcl-1 as well 
as Bcl-2/Bcl-xL were not highly sensitive to 483LM, the use of the Bcl-2/Bcl-xL inhibitor ABT-
263 was able to aid in inducing synergistic cell death. This previous data, in addition to the in vivo 
efficacy, indicates that understanding the mechanism of cancer survival using functional assays 
such as BH3 profiling can help assess the response to drugs, which is a major progress in the field 
of personalized medicine. 
 
4.4 Materials and Methods 
 
BH3 profiling 
Peptides; Bim (141-166) and Noxa (20-45) were purchased from Genbio synthetic peptide. BAD 
(102-128) and MS1 (RPEIWMTQGLRRLGDEINAYYAR-NH2)[14] were synthesized on an ABI 
433A peptide synthesizer, starting the synthesis with Rink amide resins. Cells were suspended in 
DTEB prepared as reported [19]. The cells were added into a 384 well plate (Corning #3573) in 
triplicates on wells containing peptides, 1 μM JC-1 (Assay Biotech #Z0344), 40 µg/ml oligomycin 
(Acros Organics #230350250), 5 mM 2-mercaptoethanol (Fisher Bioreagents #BP176) and 
digitonin (Sigma #D141). Digitonin concentration was 0.0025% for MM cell lines, Leukemia, 
HNSCC, and pancreatic cancer cell lines except 0.005% for PANC-1.  25,000 cells per sample 
were used for MM cell lines, 50,000 cells for Leukemia cell lines, and 10,000 for pancreatic and 
HNSCC cell lines. Fluorescence was continuously monitored at 490 nm excitation and at 590 nm 
emission every 5 min for 180 min on a Biotek synergy H4 plate reader, and data was analyzed 
using GraphPad Prism 6.01. Percent mitochondrial depolarization was calculated using the 90 
minutes for BH3 profiling using 483LM and ABT-263, and all others calculated at the 180 minutes 
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time point, except HNSCC where the AUC was measured as compared to the positive (Carbonyl 
cyanide-4-(trifluoromethoxy)phenylhydrazone) FCCP (Sigma #c2920) and negative (DMSO) 
controls.  
 
Cell culture  
HNSCC were provided by Dr. Chad Brenner and Dr. Thomas Carey. The cells were cultured in 
DMEM (Gibco #11965-092), supplemented with 1/100th volume of penicillin/streptomycin 
(Gibco #15140-122), 100 µM (1x) of non-essential amino acids (Gibco #11140-050) and 10% heat 
inactivated fetal bovine serum (Corning #35-010-CF).  Pancreatic cancer and leukemia cell lines 
were obtained from the American Type Culture Collection (ATCC) and cell cultured in DMEM 
(Gibco #11995-065) and RPMI 1640 (Gibco #11875093) respectively except BxPc3, which was 
cultured in RPMI 1640. In both cases, the media was supplemented with 1/100th volume of 
penicillin/streptomycin and 10% heat inactivated fetal bovine serum. MM cell lines were obtained 
from ATCC and cell cultured in RPMI 1640 media (Hyclone #SH30027.02) supplemented with 2 
mM (1x) of L-Glutamine (Gibco #25030-081), (1x) of Anti-Anti (Gibco #15240-062), 10 mM of 
HEPES (Gibco #15630-080), 1 mM (1x) of sodium pyruvate (Gibco #11360-070) and 10% heat 
inactivated fetal bovine serum (Atlanta Biologicals). 
 
MTT assay 
MTT assay cell proliferation was assessed using the 3-(4,5- dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay. Cells were seeded at 20,000 cells/well (MM cell lines) 
except MM.1S (30,000 cells/well), 15,000 cells/well (Leukemia cell lines), and 5,000 cells/well 
(pancreatic cell lines) in transparent 96-well plates and treated for 72 h, after which 10 µL of MTT 
(5 mg/mL in PBS) was added to each well (Amresco #0793). The wells were incubated for an 
additional 4 h at 37oC. The MTT formazan precipitate was dissolved using 100 µL SDS 1 g per 10 
ml of 0.01M HCl and incubated overnight. The mitochondrial activity, reflecting cell growth and 




siRNA silencing of Mcl-1 
500,000 cells /well/2.25ml of UM49 and UM110 were plated in 6-well plates in their growth media 
on day 0. On day 1, siRNA was complexed with Lipofectamine™ 2000 (Life Technologies) 
according to manufacturer's instructions and the cells were incubated with 44nM Mcl1 siRNA 
(Dharmacon # J-004501-15) and scrambled control (Dharmacon #D-001810-10-05) in Opti-MEM 
medium (Invitrogen) for 24 h. 
 
Determination of caspase activity 
H929 cells were seeded in 12-well plates at 0.5 × 106 cells/well. After 4 h of treatment with 
different concentrations of the compounds, caspase 3 activity was determined using the 
fluorometric substrates DEVD-AFC, according to the manufacturer’s protocol of Caspase-3 
fluorometric assay kit (BioVision). The calculation of caspase 3 activity is presented as the fold 
change relative to DMSO treated cells. 
 
Analysis of apoptosis 
To determine the induction of apoptosis, MM cells were plated in 12-well plates at 0.2 × 106 
cells/well and treated with various concentrations of tested compounds. After 4 or 24 h, cells were 
harvested, washed two times with PBS, and treated with APC-Annexin-V (Biolegend #640941) 
according to manufacturer’s protocol. HNSCC cells were plated in 12-well plates at 0.2 x 106 
cells/well overnight at day 0. On day 1, the cells are treated with various concentrations of 
compounds for 24 h. The cells are then stained with APC-Annexin-V (Biolegend), according to 
protocol and propidium iodide (MP Biomedicals #0219545810), to final concentration of 25 
µg/ml. The percentage of cells undergoing apoptosis was assessed by flow cytometry within 1 h 
and analyzed using WinList 8.0. Apoptosis was also determined in the presence of Z-VAD-FMK 
(Bachem # N15100005), pan caspase-inhibitor. For this purpose, cells were pretreated with 100 





Smac release assay 
4x106 of H929 cells were treated with compound (100 mm cell culture dish). After 4 h treatment, 
cells were washed with PBS, and re-suspended in digitonin buffer (20 mM HEPES [pH 7.4], 10 
mM KCl, 2.5 mM MgCl2, 1 mM EDTA, 700 µg/ml digitonin, 250 mM sucrose, and 1 mM DTT) 
supplemented with protease inhibitors cocktail (Biotool #B14002), and incubated for 90 seconds. 
Cytosolic fractions were separated by centrifugation at 13,200 rpm, 4oC for 10 min. Levels of 
cytosolic Smac were measured using a Smac/DIABLO antibody (GenLantis # ABI248). 
 
JC-1 mitochondrial membrane potential assay 
The mitochondrial membrane potential (ΔΨm) was determined by using JC-1 (Assay Biotech # 
Z0344). 0.1 x 106 Cells/100 µL were plated and treated with compounds for 4 h, with one sample 
treated with FCCP (Sigma #c2920) as a positive control. 100 µg/ml JC-1 was prepared using 37oC 
PBS and 10% DMSO. 10 µL of JC-1 was added to the 100 µL of cells to have 10 µg/ml final 
concentration and was incubated for 30 minutes. Cells were transferred into 1.5 microcetrifuge 
tubes and washed twice with 37oC PBS (0.6 rcf, 5min, room temp.). Pellets were resuspended in 
100 µL of PBS and transferred to black round bottom 96 well plate (Cornin #3792). Fluorescence 
was detected at Ex.535/Em.595 (aggregate) and Ex.485/Em.435 (monomer). Data was analyzed 
using GraphPad Prism 6.01 and presented as ratio of aggregate/monomer fluorescence. 
 
Immunoprecipitation 
4 x 106 of H929 cells/10 ml of growth media were treated with different concentrations of 
compound for 24 h. Cells were washed with PBS then lysed using NP-40 lysis buffer (50 mM Tris 
[pH 7.4], 150 mM NaCl, 1 mM EDTA, 0.5% [v/v] NP-40 and 1 mM DTT) and protease inhibitors 
cocktail (Biotool #B14002). Cell lysates (500 μg) were precleared and then subjected to 
immunoprecipitation by adding 3 μg of anti-Mcl-1 antibody or IgG antibody (Santa Cruz #sc-
2025) and incubated overnight at 4ºC. 20 µL of A/G sepharose beads (Santa Cruz #sc-2003) were 
added and incubated for 2 h at 4ºC, followed by centrifugation of samples. The beads were washed, 
resuspended in 40 µL of 4x Laemmli buffer, boiled, and supernatant was used for western blot 
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analysis. The primary antibodies used are: Anti-Mcl-1 Ab-1 (Clone RC13) (ThermoFisher 
Scientific #MS681P1), Anti-BAK (ThermoFisher Scientific # PA1-31513), and Anti-HSP90 
(Santa Cruz # sc-7947). 
 
Western blot analysis 
0.1x106/100 µL of H929 cells in 12 replicates in a 96-well plate were treated with compounds and 
harvested after 4 h. Cells were lysed using RIPA buffer (ThermoFisher Scientific #89900) and 
protease inhibitors cocktail (Biotool #B14002). Total cell lysates were subjected to 
electrophoresis, then transferred to PVDF membranes, followed by incubation with primary 
antibody. Visualization of blots was performed using the chemiluminescent reagent Amersham 
ECL Prime (GE Healthcare Life Sciences # RPN2232). The primary antibodies used are: Mcl-1 
Ab-1 (Clone RC13) (ThermoFisher Scientific #MS681P1), PARP (Cell Signaling #9542), and β-
Actin (GenScript #A00702).  
 
In vivo efficacy studies 
Twelve Severe Combined Immunodeficiency (SCID) mice were xenografted with 1.2 million 
human H929 cells. After one week, four mice were treated daily with one IP injection dose of 
483LMLM at 30 mg/kg and the other four mice are treated at 60 mg/kg. Four control mice were 
injected with the IP vehicle. Treatment ended at day 10 and four control mice, two 30 mg/kg, and 
three 60 mg/kg. The two remaining 30 mg/kg mice and the 60 mg/kg mouse were sacrificed after 




Ahmed Mady performed all experiments reported in this chapter except the in vivo efficacy study 
which was performed by Dr. Luke Peterson in Dr. Moshe Talpaz’s lab at the Department of 
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CHAPTER 5  
Summary and future directions 
5.1 Summary  
  
 There has been a marked progress in cancer research, especially with significant 
understanding of traits that are acquired by normal cells in order to transform to cancer. This has 
led to the initiation of a vast number of drug discovery campaigns to develop drugs that modulate 
these traits. One of the hallmarks of cancer is resistance to apoptosis. Evading apoptosis 
contributes to tumor proliferation and progression, as well as resistance to therapeutic interventions 
that act by triggering the activation of the apoptotic pathway. Thus, it is important to understand 
the mechanisms that contribute to apoptosis resistance in cancer cells. Apoptosis regulates various 
conserved physiological and pathological processes. The Bcl-2 family of proteins regulates the 
intrinsic apoptotic pathway through a network of protein-protein interactions between pro-
apoptotic and anti-apoptotic proteins. Cell fate is tightly controlled by these interactions. The 
upregulation of anti-apoptotic proteins and/or downregulation of pro-apoptotic proteins are 
mechanisms activated by cancers to block the induction of apoptosis. The tumorigenic potential of 
Bcl-2 family proteins was observed in combination with overexpressed Bcl-2 and c-Myc, 
promoting proliferation and immortalization of pre-B cells.[1, 2] Another anti-apoptotic protein is 
Mcl-1, which was identified when the MCL-1 gene was isolated from maturing ML-1 myeloid cell 
leukemia.[3] Overexpression of Mcl-1 has been associated with poor prognosis of human cancers 
as well as resistance to chemotherapeutics.[4-8] Consequently, there are efforts to develop drugs 
that could block the function of Mcl-1, either indirectly by inhibiting its expression or inducing its 
degradation, or directly by targeting its interaction with pro-apoptotic partner proteins by 
developing BH3 mimetics.[9] 
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 In Chapter 2, we employed an integrated screening approach, combining high throughput 
and virtual screening to identify novel chemical classes as inhibitors of myeloid cell leukemia-1 
(Mcl-1), a potent anti-apoptotic protein. For this purpose, we used the PubChem BioAssay 
Database to further study 1214 positive hits that were identified from our previously reported dual-
readout HTS assay that combined two assay technologies, FP and FRET, into one system using 
Mcl-1 either with labeled Noxa or Bid BH3 derived peptides.[10] A high hit rate in HTS campaigns 
can make the identification of the most promising hits a challenging task, and novel strategies to 
simplify this process are desired. Therefore, to further improve the output and the quality of the 
identified inhibitors, as well as to incorporate the structure-based knowledge of the interactions 
between Mcl-1 and number of BH3 peptides, we have integrated in silico target-based screening 
for selection of the most promising hits for further validation. 37 compounds were purchased and 
evaluated in a complementary set of biochemical and biophysical assays to determine the binding 
potency against Mcl-1. 20 hits were confirmed to have activity against Mcl-1 with different 
chemical scaffolds. We further studied one of the hits, E238, by synthesizing and testing a small 
library of triazine-based analogs and reaching 10-fold improvement in binding compared to the 
original hit compound. We also demonstrated Bax/Bak dependent cellular activity with E305 as 
well as Mcl-1 selectivity.  
 In Chapter 3, we used the knowledge gained from the previously synthesized small library 
and analyzed the established SAR through various biochemical assays. Consequently, we 
performed a structural-based design of a new class Mcl-1 inhibitors. The utilization of molecular 
modeling supported by HSQC-NMR led to designing the new inhibitor 368LM with a new 
chemical scaffold. Several analogs were synthesized to explore the interactions with the BH3 
binding pocket of Mcl-1. Three of the compounds developed (396LM, 382LM, and 462LM) were 
successfully co-crystallized with Mcl-1. These X-ray crystal structures significantly enhanced our 
understanding of the binding interactions between the inhibitors and Mcl-1, and guided us to 
optimize their binding affinities. Further drug design efforts led to the development of 483LM, 
487LM and 491LM as potent and selective Mcl-1 inhibitors confirmed by FP, TR-FRET, and 
SPR competitive assays. 483LM disrupted the interaction between biotinylated Noxa and 
endogenous Mcl-1 protein in 2LMP cell lysate and also inhibited the function of Mcl-1 in a cell-
free functional assay, disrupting its interaction with introduced Bim BH3 peptide. Treating PANC-
1 with 483LM for 6 h disrupted Mcl-1/Bak interaction in a co-immunoprecipitation assay. 
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Furthermore, compound 483LM selectively sensitizes Eμ-myc lymphomas overexpressing Mcl-
1, but not Eμ-myc lymphomas overexpressing Bcl-2 or Bcl-xL, correlating with the selectivity 
profile generated via FP assay.  Using MEFs model cell lines, 483LM demonstrated Bax/Bak 
dependent induction of cell death. 
 In Chapter 4, we demonstrated the importance of developing functional assays that can aid 
in predicting the best chemotherapeutic to benefit cancer patients. One of these functional assays 
is BH3 profiling, where the mitochondria is interrogated by various BH3 pro-apoptotic peptides 
with different selectivity profiles against anti-apoptotic proteins. With this method, the anti-
apoptotic protein on which a certain type of cancer depends can be determined. Using BH3 
profiling, we screened a panel of solid and hematological tumors. We detected different 
dependence profiles in the tested cell lines. Using 483LM and ABT-263 in BH3 profiling exhibited 
a similar effect to Noxa and Bad BH3 peptides, respectively. A correlation between mitochondrial 
depolarization induced by MS1 and Noxa with expression ratio of Mcl-1/Bcl-xL was established 
in the investigated multiple myeloma and leukemia cell lines, respectively, indicating that these 
two proteins play a major role in controlling their cell fate. Cell viability and synergistic studies 
with 483LM and ABT-263 recapitulated the BH3 profiling data generated. We further investigated 
the mechanism by which compound 483LM induces cell death in the Mcl-1 sensitive cell line 
H929. We demonstrated the ability of the compound to disrupt Mcl-1/Bak interaction, induce 
mitochondrial membrane depolarization, and trigger the release of Smac from mitochondria to the 
cytosol. Consequently, caspase 3 is activated and PARP is cleaved, indicating the induction of the 
apoptotic pathway. This data was encouraging to proceed with in vivo efficacy studies, where 
483LM demonstrated, in H929 mouse xenograft model, dose-dependent inhibition of tumor 
growth. The inhibition of tumor growth was sustained for more than 7 days after stopping the 60 
mg/kg treatment.  
 
5.2 Impact and significance of the dissertation studies 
 
 The research presented in the dissertation reports discovery and development of potent and 
selective small-molecule Mcl-1 inhibitors as disruptors of anti- and pro-apoptotic protein-protein 
challenging interactions.  The most important scientific contributions are:  
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- The use of integrated approach combining high-throughput screening results (deposited in 
PubChem database) and computational structure-based docking, allowed identification of 
diverse and novel chemical scaffolds as potential lead compounds for further development.  
- Applying structure-based design, followed by medicinal chemistry campaign and SAR 
studies, novel chemical class of Mcl-1 inhibitors with 2,4,5-substituted benzoic acid 
scaffold was developed.  
- Potent and selective inhibitors exhibit on-target Mcl-1 cellular activity and in vivo activity 
in human multiple myeloma xenograft model as single agents. These compounds, used as 
chemical tools, will have significant impact on further understanding and validating Mcl-
1 as therapeutic target. 
- Established BH3 profiling functional assay and understanding the survival dependence of 
human cancers will allow further implementation of this assay towards personalized 
medicine, to screen patient samples, and determine the population which will benefit the 
most of the treatment with Mcl-1 inhibitors or other apoptosis inducers, as single agents or 
in combination with standard chemotherapy.  
 
5.3 Future directions 
 
Optimization of physicochemical properties of inhibitors 
 As stated previously, development of PPI inhibitors is a challenging process due to the 
hydrophobic nature of the PPI interfaces. Several groups have developed highly potent indole-
based Mcl-1 inhibitors with limited cell permeability [11-13], and none of these compounds were 
shown to have in vivo efficacy. [14] There is a necessity to develop Mcl-1 inhibitors with enhanced 
physicochemical properties to develop drug-like molecules that can be taken further to clinical 
studies. Our most potent Mcl-1 inhibitor, 483LM, demonstrated encouraging in vivo efficacy 
through intra-peritoneal (IP) injections. However, the physicochemical properties of 483LM (logP 
= 9.37 and solubility is up to 15 µM in PBS buffer with 6% DMSO) require further chemical 
optimizations in order to improve the oral bioavailability. This will be a significant step towards 




Implementing novel functional methods for precision medicine 
 The use of functional assays to monitor tumor response in patients is the future of precision 
medicine. This can guide clinicians to design the most optimum intervention protocol that is most 
beneficial to cancer patients. We performed BH3 profiling on established cancer cell lines. It is 
important to extend the assay to primary cells in order to correlate the results of the assay with the 
predicted outcome of patient treatment. The use of recent dynamic BH3 profiling techniques will 
be important to determine the best chemotherapeutics to treat a patient’s cancer in a matter of 
hours, instead of waiting for one or more days to determine the best treatment. [15]  
 
Using Mcl-1 inhibitors in single or combination therapy 
We have demonstrated the in vivo efficacy of an Mcl-1 inhibitor as a single agent on H929 
xenograft mouse model. Based on BH3 profiling, H929 is dependent on Mcl-1 for survival. 
Various types of cancer develop resistance to certain chemotherapeutics, due to upregulation of 
Mcl-1. As a result, it will be important to determine the in vivo efficacy of Mcl-1 inhibitors in these 
resistant types of cancer, as single agents or as combination therapy to the already used 
chemotherapeutics. It is yet to be determined if the use of Mcl-1 inhibitors can shift the apoptotic 
balance of these resistant cancers to induce elimination by a combined chemotherapeutic agent.  
 Overall, the studies presented in this dissertation will open the door for further research 
efforts to develop Mcl-1 inhibitors that can be used to treat various types of cancer, either as single 
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